The Impact of Climate Policies on Financial Markets: Evidence from the EU Carbon Border Adjustment Mechanism

Mengjie Shi* Yupu Zhang[‡]

Christoph Meinerding[¶]

This version: February 7, 2025

Abstract

The introduction of the EU Carbon Border Adjustment Mechanism (CBAM) has triggered statistically significant negative stock market responses for firms within the EU. Comparing EU customers that have non-EU suppliers in CBAM-affected industries with their nontreated peers in the control group, we find an extra cumulative abnormal return of up to -1.3 percentage points over our main five-day event window around December 13, 2022. Furthermore, we document substantial anticipatory market responses reflecting updated beliefs about broader climate policy developments going forward. This paper is the first to provide empirical evidence of carbon border tax impacts on firm valuations through international supply chains. Our findings contribute to the understanding of climate policy transmission through international trade networks and inform the debate on stranded assets resulting from environmental regulations.

Keywords: Carbon border adjustment mechanism, carbon pricing, supply chain, event study, cumulative abnormal returns, trade

JEL: G12; G14; G15; Q58

^{*}Goethe University Frankfurt and Deutsche Bundesbank. Email: mengjie.shi@bundesbank.de

[‡]University of Edinburgh Business School. Email: yupu.zhang@ed.ac.uk

[¶]Deutsche Bundesbank. E-mail: christoph.meinerding@bundesbank.de.

We thank colleagues and seminar participants at the University of Edinburgh, the Deutsche Bundesbank, and Goethe University Frankfurt, DGF 2024 (Aachen), Conference on Net Zero, Nature and Supply Chain Vulnerabilities (London), SAEe 2024 (Palma de Mallorca) and AFA 2025 Poster Session (San Francisco) for valuable comments. Special thanks go to Refet Gurkaynak, Emanuel Moench, Tobias Berg, Claudio Baccianti, Jurian Hendrikse, Ole Wilms, Christian Schlag, Luca Taschini, Ben Sila and Frank Venmans. The views expressed in this paper represent the authors' personal opinion and do not necessarily reflect the views of the Deutsche Bundesbank or the Eurosystem.

1 Introduction and Motivation

Climate policy has gained significant momentum in many countries in recent years. Among the wide range of policy measures, carbon pricing schemes stand out because they are deeply rooted in foundational theories of economics, including Pigouvian taxation and Coasean property rights. The theoretical optimality conditions are operationalized through a carbon tax or a market-based cap-and-trade framework, where marginal abatement costs are equalized across heterogeneous firms. In practice, though, these schemes come with loopholes: for one, they are not harmonized, let alone implemented globally. For another, it is usually the domestic producers who have to pay for emissions, not the consumers. Firms can thus evade the pressure from carbon pricing by engaging in carbon leakage, i.e. by shifting their production to countries with no or less stringent emissions pricing in place.

Against this backdrop, in 2023 the EU decided to introduce a new flagship climate policy instrument: the EU Carbon Border Adjustment Mechanism (CBAM). The CBAM is the world's first carbon border tax. In a nutshell, it requires the importers of certain goods to pay an import tax proportional to the carbon footprint of these goods. The CBAM complements the already existing EU Emissions Trading System (EU ETS). Ideally, it levels the playing field for production inside and outside the EU in terms of carbon pricing, discouraging carbon leakage.¹ Because of its recency, to the best of our knowledge, there is no empirical evidence examining the impact of the CBAM yet.

This paper analyzes the stock price response of firms involved in international trade to the introduction of the CBAM. To this end, we conduct a causal event study around the main legislative event on December 13, 2022. On this day, at 1:00 a.m. in the morning, the EU published a press release announcing the breakthrough in the so-called Trilogue negotiations between the European Commission, the European Parliament and the Council of the European Union.² For our main analysis, we merge seven datasets, most importantly FactSet Revere

¹For instance, the CBAM tax rate is calibrated such that the tax roughly equals the hypothetical amount that would have to be paid for EU ETS certificates, had the goods been produced within the EU.

 $^{^{2}}$ In Section 2, we provide an in-depth discussion why this agreement constitutes the main exogenous event around which we conduct our event study. But we also run a series of robustness checks for other important dates related to the CBAM.

data on customer-supplier relationships, Compustat and Worldscope data on returns and firm characteristics, and a linking table from CN goods classifiers to SIC industry codes.³ Equipped with this merged final sample, we document a set of novel empirical findings.

First and foremost, the cumulative abnormal returns (CARs) of EU customer firms with CBAM-treated suppliers are on average 1.3 percentage points lower than the CARs of their peers in our control group, when measured over a five-day event window. This basic treatment effect is strongly significant and robust to a series of robustness checks, for instance adjusting to longer event window, changing the specification of treatment and control groups, allowing the customer-supplier relationships to end before the event date, and using the Fama-French 3-factor or 5-factor model instead of the CAPM to compute abnormal returns. It is also sustained over a longer time window which includes a related policy announcement concerning a reform of the EU ETS one week later.

Albeit small at first glance, this treatment effect is remarkable for several reasons. First of all, multiplying the average treatment effect with the total market capitalization of all treated firms in our sample suggests losses above 1 billion EUR over the event window. This estimate is roughly in the ballpark of EU estimates of the expected CBAM revenues.⁴ Second, the documented treatment effect applies to customer firms *within the EU*, suggesting a spillover of the effects of climate policies along the supply chain. Third, as will become clear below, the treatment effect of the measured here should rather be regarded as a lower bound for the (unknown) total effect of the CBAM.

Fourth, our findings complement the developing empirical literature about the effect of carbon pricing on the financial performance of firms. Dechezlepretre, Nachtigall, and Venmans (2023) and Colmer, Martin, Muuls, and Wagner (2023) document that the EU ETS – while it triggered substantial carbon emission reductions – did not have notable negative side effects

 $^{^{3}}$ We thank Pierce and Schott (2012) for making this linking table publicly available.

⁴To put this into perspective, according to a press release in 2023, the European Commission expects CBAM revenues of roughly 1.5 billion EUR per year, as of 2028. Assuming that EU importers have to bear half of it (an uneducated guess concerning their bargaining power) implies annual costs of about 0.75 billion EUR. Extrapolating over 23 years (the EU aims to be carbon-neutral by 2050) and discounting generously with an equity premium of 6 percentage points results in an expected total loss of market value above 5 billion EUR. Note that this EU estimate refers to the entire universe of firms in the EU, whereas the sample used in our paper covers only publicly traded firms.

on output, profitability or employment of regulated firms during Phase 1 and 2 (2005-2012), a period with low emission prices and a very generous allocation of free allowances. These authors argue that the EU ETS may have induced productivity-increasing investments which offset the regulatory costs. However, the situation has changed. Studying the intensive margin, Bolton, Lam, and Muuls (2023) find significant negative stock price responses to changes in carbon allowance prices during Phase 3 of the EU ETS. Our paper refers to Phase 4 which, for the first time, involves a cross-border instrument to mitigate carbon leakage, and emphasizes the extensive margin of climate policy. Using a clean event study identification, our paper documents economically and statistically significant negative effects from the introduction of the CBAM, a companion policy tool to the EU ETS, when viewed through the lens of equity market investors. Summing up, carbon pricing, after all, does seem to bite and to be detrimental to the financial performance of regulated firms, both at the intensive and the extensive margin, when the pricing regime is strict enough and loopholes are closed.

We also document significant market responses which go beyond this direct impact of the CBAM. Specifically, we find anticipatory effects related to market participants' updating beliefs regarding broader climate policy developments. Our empirical strategy exploits the temporal separation between the announcement of the CBAM agreement and subsequent announcements of EU ETS reforms, particularly concerning the allocation of free emission allowances. These free allowances are supposed to sustain the global competitiveness of firms in specific sectors whose competitors abroad do not face the burden of carbon pricing. When the CBAM becomes effective, this support will no longer be needed and will be phased out. However, while these policy instruments were negotiated concurrently, the official press release on our event day only refers to the CBAM. Still, we posit that this announcement served as a credible signal regarding the imminent phase-out of free allowances – a policy change that was in fact agreed on one week later. Furthermore, the CBAM press release included the EU's explicit commitment to expand its scope to encompass all goods currently under EU ETS jurisdiction until 2030. This goes far beyond the initial subset of affected goods where we identify our primary treatment effect.

To systematically analyze these anticipatory effects, we construct various treatment group specifications. For our baseline analysis, a customer firm needs to have suppliers that satisfy two requirements in order to be counted as treated by the CBAM: (i) supplier location outside EU jurisdiction (the "location treatment") and (ii) product coverage under CBAM regulations (the "industry treatment"). For the beliefs updating hypotheses, we analyze these two requirements in isolation. Our empirical analysis reveals that both of them independently generate economically significant effects, each one being associated with approximately -1 percentage point average cumulative abnormal returns.

The industry treatment effect highlights market participants' revised expectations regarding the free allowance allocation mechanism. It captures the anticipated increase in the financial burden on EU-based producers. Similarly, the location treatment effect provides compelling evidence of market participants' forward-looking assessment of the CBAM's scope expansion. Despite the initial specification of CBAM-affected goods, the press release explicitly articulates the intention to encompass all EU ETS-covered goods by 2030. The significant market reaction we document suggests high credibility of this policy commitment among investors. Overall, our findings suggest substantial market repricing of climate policy risk, even for firms not directly affected by the initial CBAM implementation. The stock returns align with theoretical predictions regarding rational expectations formation in response to credible policy commitments.

A set of further analyses complements and supports our key takeaways. In our baseline case, we analyze the returns of EU customer firms because they are more relevant for policymakers within the EU. But of course it is natural to also study the cumulative abnormal returns of supplier firms located outside the EU around December 13, 2022. Because the data for suppliers is arguably much noisier, we find mostly insignificant treatment effects, but in magnitude the effects are comparable to those for customer firms within the EU. This suggests that the financial burden arising from the CBAM is shared among customers and suppliers, at least when viewed through the lens of equity investors. Given the limitations of our current dataset, there is however scope for further research on this question.

We also conduct similar event studies around other important legislative dates related to the CBAM. This is complicated by the fact that the CBAM is part of a larger set of EU climate policies subsumed under the so-called "Fit for 55 package", so that there are often news about several climate policies released on the same day. Still, our partial treatments (location treatment and industry treatment) are informative on these dates because none of the other, perhaps conflicting policies are targeting cross-border trade. We find cumulative abnormal returns of up to -2 percentage points around some of these dates. Overall, these results generally support the intuition described above that the introduction of the CBAM and the associated climate policy reforms do affect the financial performance of newly regulated firms negatively.

We close the paper with a series of robustness checks concerning the length of the event window, the exact composition of our treatment and control group, customer-supplier relationships ending prior to the event date, or the asset pricing models used to compute abnormal returns. Our key results turn out to be very robust to such choices.

Related Literature Given the lack of empirical examples, the research on the financial impact of *global* carbon pricing schemes is still in its infancy. Since the CBAM legislation has been adopted only recently, our paper is – to the best of our knowledge – the first to study the financial market response to carbon border taxes. There is also – to the best of our knowledge – no study that analyzes the effects of carbon pricing along the supply chain empirically. Quantitatively, our paper documents that the potential losses of suppliers and customers caused by the CBAM regulation can be substantial. This stands in contrast to parts of the literature cited above which document only negligible negative effects of the EU ETS or other carbon pricing schemes on the performance of regulated firms during early phases of the EU ETS. A comprehensive survey of this early literature is provided by Martin, Muûls, and Wagner (2016).⁵

Still, our paper can be connected to a few strands of literature more generally. Firstly, our paper contributes to the broader discussion about the effectiveness and the design of climate policies. As previously noted by Blanchard, Gollier, and Tirole (2023), various existing climate

⁵Besides the papers cited above, see, e.g., Martin, de Preux, and Wagner (2014), Jaraite-Kaukauske and Maria (2016), Marin, Marino, and Pellegrin (2018), Loeschel, Lutz, and Managi (2019), Teixido, Verde, and Nicolli (2019), Klemetsen, Rosendahl, and Jakobsen (2020), Trinks and Hille (2024) for the responses of various quantities like employment, investment or profitability at the firm level. The responses of stock prices to changes in emission allowance prices during Phases 1 and 2 of the EU ETS have been studied, among others, by Oberndorfer (2009), Veith, Werner, and Zimmermann (2009), Mo, Zhu, and Fan (2012), Bushnell, Chong, and Mansur (2013), Scholtens and van der Goot (2014), Oestreich and Tsiakas (2015), Huiming Zhu and Yu (2018) Millischer, Evdokimova, and Fernandez (2023).

policy instruments, including carbon markets, carbon taxes, and green subsidies, often appear incoherent and should be considered jointly in specific contexts.⁶ Among them, carbon pricing is a pivotal solution to restore economic and environmental efficiency and should be part of the optimal mix of climate policies. Nevertheless, international climate agreements come with coordination failure due to free-riding problems, creating obstacles to forging effective global climate policies. Nordhaus (2015) therefore suggested the idea of a climate club, which is an agreement among countries to undertake harmonized climate actions. If the participation in such a club is incentivized properly, this coordination device may solve free-rider problems. Our paper studies the potential consequences of the most recent climate policy innovation, the EU CBAM. First and foremost, the CBAM is designed to address carbon leakage directly, but it can also be regarded as such an incentive for third countries to form a climate club with the EU, as emphasized by Beaufils, Wanner, and Wenz (2024). Farrokhi and Lashkaripour (2024) study and compare theoretical properties, effectiveness and efficiency of these two trade policy instruments in great detail.⁷ Specifically, we examine the financial market reaction to the announcement of such a policy. There is also a large empirical literature that tries to find evidence in favor of carbon leakage, but the results are overall inconclusive so far.⁸

A substantial body of literature, mainly in macroeconomics, studies the optimal design of climate policies in open economy models. Examples are Larch and Wanner (2017), Weisbach, Kortum, Wang, and Yao (2023), Ernst, Hinterlang, Mahle, and Stähler (2023), Böhringer, Fischer, Rosendahl, and Rutherford (2022), Fischer and Fox (2012), Al Khourdajie and Finus (2020), Böhringer, Carbone, and Rutherford (2016), Salib (2024). A survey of this literature is provided by Fontagne and Schubert (2023). However, except for Fowlie, Petersen, and Reguant (2021), no prior studies have analyzed the economic impact of such a policy in empirical real-world

⁶There is an extant literature on each of these instruments. See, e.g., Calel and Dechezleprêtre (2016), Cui, Wang, Zhang, and Zheng (2021), Van den Bremer and Van der Ploeg (2021) for carbon markets; Elliott, Foster, Kortum, Munson, Cervantes, and Weisbach (2010), Marron and Toder (2014) for carbon taxes; Allcott, Knittel, and Taubinsky (2015), De Groote and Verboven (2019)) for subsidies.

⁷In fact, the preamble of the official CBAM regulation contains a paragraph that explicitly calls for the development of further cooperation with third countries to establish a climate club "in order to promote the implementation of ambitious climate policies in all countries and pave the way for a global carbon pricing framework".

⁸See, e.g., Naegele and Zaklan (2019), Dechezlepretre, Gennaioli, Martin, Muuls, and Stoerk (2022), Fowlie and Reguant (2022), Colmer, Martin, Muuls, and Wagner (2023), Bolton, Lam, and Muuls (2023).

settings.

Furthermore, our paper also contributes to the literature on environmental policy and international trade. Early works have explored the impact of trade on a country's environment. For example, Antweiler, Copeland, and Taylor (2001) argue that this impact can be categorized into three components: scale, technique, and composition, and finds that international trade can induce technological change, therefore creating net benefits for the environment.⁹ Other papers focus on how environmental regulation can affect trade flows. Separating industrialized and developing countries, Ederington, Levinson, and Minier (2005) finds the pollution abatement cost on imports from developing countries to be high. In this respect, the concept of carbon leakage explained above has received attention (Fowlie, Reguant, and Ryan (2016), Shapiro and Walker (2018)).

Lastly, our paper sits within the context of literature analyzing the effects of public policies and regulations on asset prices. Cohen, Diether, and Malloy (2013) show that the historical voting record of legislators has explanatory power for (seemingly) abnormal post-legislation drifts in the prices of stocks that are affected by certain policies. Other papers delve into the implications of monetary policy (Nakamura and Steinsson (2018)) and fiscal policy (Gómez-Cram and Olbert (2023)) for equity prices using high-frequency data. The most relevant paper is by Meng (2017), who investigates the stock market reaction to climate policy and adopts Regression Continuity Design (RDD) to evaluate the marginal abatement cost. Extending this line of research, our paper analyzes the stock market's reaction to a new cross-border climate policy by incorporating supply chain information.

The rest of the paper is structured as follows. In Section 2, we elaborate on the legislative background of the CBAM. Data and methodology are presented in Section 3. Sections 4 and 5 discuss our results, and Section 6 provides a set of robustness checks. Section 7 concludes and discusses policy implications.

⁹Similarly, Frankel and Rose (2005) find that trade tends to reduce three measures of air pollution using exogenous geographic determinants of trade as instrumental variable

2 Background information on the legislative process and theoretical predictions

The event study that we perform has two major requirements. First, we need to single out the dates on which relevant news about the EU CBAM were released. Second, we need to develop testable hypotheses based on the news that were released and on the general theory about carbon border adjustments. The former is addressed in the first subsection below, the latter in the subsection thereafter.

2.1 Timeline of political events

Table 1 summarizes the timeline of the CBAM legislation process. In the following, we will discuss these events briefly. As will become clear below, the most important and suitable date for our event study is December 13, 2022. We will therefore conduct our event studies mainly around this date.

On December 11, 2019, a few months after the European Parliament election, the newly appointed president of the European Commission, Ursula von der Leyen, gave a widely recognized speech to the new parliament, in which she laid out her plans for the so-called EU Green Deal. The CBAM was one of many climate policy initiatives that she proposed in this speech.

From a legal perspective, the EU Carbon Border Adjustment Mechanism was implemented by means of an EU regulation, i.e. a "binding legislative act which must be applied in its entirety across the EU"¹⁰. As such, the CBAM regulation had to pass the EU's so-called "ordinary legislative procedure", which involves the European Commission, the European Parliament, and the Council of the European Union with different roles. The Commission usually initializes the legislative process, but it is the Parliament and the Council that have to adopt the act eventually (so-called Codecision Procedure). A proposal can go back and forth between Parliament and Council in several rounds, until both pass the act. In order to speed up the joint decisionmaking, the EU has established an informal meeting format between Commission, Parliament and Council, the so-called Trilogue, which was also applied to the CBAM.

¹⁰See https://european-union.europa.eu/institutions-law-budget/law/types-legislation_en

Dec 11, 2019	Ursula v.d.Leyen announces EU Green Deal in a speech
Jul 14, 2021	European Commission adopts proposals for "Fit for 55 package"
Jul 14, 2021	including proposal for the CBAM
Sep 13, 2021	Committee referral announced in European Parliament
Mar 15, 2022	European Council adopts its position on the CBAM
May 92 9099	Draft report of the Committee on the Environment,
May 23, 2022	Public Health and Food Safety of the European Parliament
June 22, 2022	European Parliament adopts its position on the CBAM
July 11, 2022	Beginning of Trilogue meetings (Commission, Parliament, Council)
Dec 13, 2022	Informal provisional agreement about CBAM reached
Feb 09, 2023	Parliamentary Committee approves official text of the Trilogue
reb 09, 2023	agreement concerning CBAM (and other parts of "Fit for 55 ")
Apr 18, 2023	CBAM (and other parts of "Fit for 55") formally adopted by
Apr 16, 2025	the European Parliament
Apr 25, 2023	CBAM (and other parts of "Fit for 55 ") formally adopted by
Apr 25, 2025	the European Council
May 10, 2023	Final act officially signed
May 16, 2023	Publication in the Official Journal of the EU
Oct 01, 2023	CBAM goes into effect (transitional period, reporting obligations only)
	Importers have to surrender CBAM certificates for imports of listed goods
Jan 01, 2026	(certificates can be purchased throughout the year, official declaration
	for a given year is due by May of the next year)
Lap 01 9020	Intention that CBAM will apply to all goods covered by EU ETS
Jan 01, 2030	(proposal still to be worked out by EU legislative bodies)

Table 1: Timeline of events related to the CBAM

This ordinary legislative procedure is visible in the timeline of events in Table 1. The legislative process was initiated through the adoption of a proposal by the Commission on July 14, 2021. This proposal was then passed on to the Parliament where the Committee on the Environment, Public Health and Food Safety was in charge of it. After both the Parliament and the Council had formulated their opinions on the CBAM proposal, the series of Trilogue meetings started on July 11, 2022, and resulted in an informal agreement on December 13, 2022. More precisely, the press release about the agreement was published at 1:00 am in the morning of December 13, 2022. After this breakthrough in the negotiations, it then took a few weeks to clarify further details. The final version of the CBAM regulation was approved by the responsible Parliamentary Committee on February 09, 2023. Both the European Parliament and the European Council adopted this final version of the CBAM regulation officially in April 2023.

We conduct our event study mainly around one date – December 13, 2022 – when the breakthrough in the Trilogue negotiations was reached. There are two major reasons for this choice. First of all, many of the candidate dates listed in Table 1 are confounded by multiple legislative events happening on the same day. The CBAM regulation is part of a broad legislative agenda that is publicly referred to as the "Fit for 55 package". This package concretizes the ideas laid out in the inaugural EU Green Deal speech from December 11, 2019. It includes, for instance, changes to the EU Emission Trading System (like an extension to further sectors and a stronger reduction of the emissions cap), a new emissions trading system for the road transport and building sector, the phasing-out of fossil fuel cars by 2035, and most importantly, the phasing-out of the free allowance system for a number of sectors. This free allowance system was established at the beginning of the EU ETS in order to shield certain sectors which are heavily exposed to global competition with countries which do not have a carbon pricing scheme in place. In order to level the playing field internationally, firms in these sectors were granted free allowances generously. This system of free allowances will now come to an end together with the introduction of the CBAM.

All these policies were negotiated very much in parallel with the CBAM. For instance, the first detailed proposal of the "Fit for 55 package" – including the first proposal for the CBAM – was adopted and publicly announced by the European Commission on July 14, 2021. Moreover, in its plenary meetings on April 18, 2023, the European Parliament voted on both the CBAM and the reform of the EU ETS. From the list of events in Table 1, December 13, 2022, is the only major event that is not contaminated with other EU climate policy decisions happening on the same day. The Trilogue negotiations for the CBAM were closely connected to, but formally independent from the negotiations of the EU ETS reform. In fact, the Trilogue agreement concerning the phasing-out of free allowances was reached one week later, on Sunday, Dec 18, 2022.

Second, the information that was released on December 13, 2022, can be considered as both novel and important for financial investors. To see this, one has to dig a little deeper into the details of the CBAM negotiations. The legislation proposal of the EU Commission on July 14, 2021, was already very advanced. For instance, it contained an initial list of goods (with CN codes) that the CBAM should cover. The proposal was also very detailed about how the carbon border tax should be implemented via trading of CBAM certificates, and also outlined penalties for misbehavior. Roughly speaking, for every import into the EU, importing firms located inside the EU need to surrender CBAM certificates, which can be purchased (and traded) at any time at a price equal to the average EU ETS price in the respective week. This general idea of the CBAM was not changed during the entire negotiation process. Clearly, a large part of the regulation is devoted to rules how to measure, declare and audit the amount of emissions for which CBAM certificates need to be surrendered. The initial proposal also contained the intention that the CBAM should be extended to all goods covered by the EU ETS until 2036. To sum up, the overall structure and outline was very clear already from this initial proposal.

Still, many details of the CBAM were changed or clarified during the following negotiations. Overall, the final CBAM regulation can be regarded as stricter than the initial proposal. The initial list of CBAM-affected goods was extended towards hydrogen, certain indirect (i.e., Scope 2) emissions, certain precursors and downstream products like screws and bolts and similar products of iron and steel. The penalties for misbehavior were strengthened. Moreover, many details concerning the alignment of the CBAM with the EU ETS (for instance as regards the allocation of free allowances) had to be settled, also with an eye on the compatibility of the CBAM with WTO rules. Importantly, this alignment also implies that the CBAM should be extended towards a larger number of goods in the near future. The gradual phasing-in of the CBAM was decided to be much faster than initially proposed. The CBAM is supposed to be extended to all goods covered by the EU ETS until 2030. Finally, the institutional design was adjusted, with certain parts of the governance being centralized at the EU level. The tax will be collected by the national authorities of the EU member states, but the declarations of purchased allowances will have to be filed to an EU-wide CBAM registry administered by the EU Commission, presumably facilitating a proper enforcement of the CBAM.

Naturally, these adjustments represent a compromise between the positions of the Parliament and the Council that was reached during several rounds of negotiations. For instance, in its positioning on June 22, 2022, the Parliament pushed for the extension of the list of CBAMaffected goods and the stricter timeline. On the other hand, the semi-central governance structure rather reflects the position of the Council adopted on March 23, 2022. The compromise between these positions was published in a three-page press release on December 13, 2022, sketching the Trilogue agreement as outlined above.¹¹ We therefore view this date as the one containing the largest amount of news for financial markets that can be related specifically to the CBAM. The complete and final version of the legislative text was released alongside the final decision of the Parliamentary Committee on the Environment, Public Health and Food Safety on February 09, 2023. This version was then officially adopted by the European Parliament and the Council of the European Union in April 2023. But the key features of this final legislation were publicly known since December 13, 2022.

2.2 Developing hypotheses

From the political developments and the design specifications of the CBAM, we can deduce our main testable hypothesis. We conjecture to see a negative abnormal stock return of firms that are subject to the CBAM regulation as opposed to non-regulated firms. Following the canonical framework of Campbell and Shiller (1988), we posit that carbon pricing affects firm valuations through two primary theoretical channels: cash flows and discount rates.

The expected cash flow channel operates through direct impacts on firms' future operational ¹¹See https://ec.europa.eu/commission/presscorner/detail/en/ip_22_7719

costs, with the magnitude being determined by, for instance, import intensity, cost pass-through capabilities, and market structure. Overall, the CBAM reduces the expected cash flows of firms which import the specified goods.

The discount rate channel emerges through exposure to systematic risks like carbon price volatility, regulatory uncertainty, or international trade frictions, potentially affecting firms' cost of capital. Depending on the financial situation of a firm and on its import share, the CBAM may increase the risk of its cash flows substantially, which could result in higher cost of capital (i.e. discount rates) to the extent that this additional cash flow risk is systematic and not diversifiable. Both effects imply a decrease in regulated firms' stock prices upon announcement of the CBAM, relative to the stock prices of unregulated firms.

A few design features need to be taken into account more specifically, though. First of all, we will test the hypothesis on firms located within the EU. It is the importing firm (within the EU) which has to report the emissions of its imports and purchase the CBAM certificates, not the producer (located outside the EU). To what extent the importer can pass on the additional costs to the producers, depends on the relative bargaining power of the two. But it is reasonable to assume that importers will have to bear at least a significant share.

Second, the CBAM puts a price on carbon emissions that were previously unpriced, i.e., it operates at the extensive margin, not the intensive margin. Third, the CBAM covers only a few goods categories, for which carbon emissions are important and relatively easy to measure and report, but not all imports. When constructing our treatment and control group, we will thus separate firms using two criteria: (i) whether they have suppliers outside the EU (ii) and which goods they import.

One can construct (seeming) counterarguments against our main hypothesis. For instance, the CBAM changes the relative competitiveness of domestic and foreign producers. If the CBAM makes foreign imports less appealing, thereby making domestic products more competitive, customers may switch their suppliers to domestic ones. However, while this channel may reduce the magnitude of the results, it cannot fully offset the expected cash flow and discount rate effects above. First, switching suppliers is costly, for instance in terms of search costs. Second, it is unreasonable to assume that a firm would be overall financially better off with a new domestic supplier than in the situation without CBAM and with the incumbent foreign supplier. If this was the case, the incumbent customer-supplier relationship would have been suboptimal to begin with. Third, the costs already borne by EU-domiciled upstream producers due to the pre-existing EU ETS are not reduced by the CBAM regulation. If anything, these upstream producers are expected to be negatively affected by the phasing-out of free allowances in the future. To sum up, the possibility to switch suppliers cannot fully offset our results at least in the short run.

Finally, the policy process described above gives rise to two additional testable hypotheses. These hypotheses relate to market participants' updating of beliefs regarding two further climate policy reforms down the road: (1) the phasing out of free allowances and (2) the extension of the CBAM to more goods.

Concerning (1), The CBAM is part of the larger "Fit-for-55" package, which includes, among others, a phasing-out of the system of free allowances within the EU ETS. These free allowances exist mainly in order to sustain the global competitiveness of firms in certain sectors, given that their competitors abroad do not face the burden of carbon pricing. When the CBAM becomes effective, this support will no longer be needed. In fact it would even violate WTO rules. The decision to end the system of free allowances was publicly announced one week after the CBAM decision, but it is closely connected by construction. Therefore market participants likely interpreted the CBAM announcement as a strong signal that also the free allowances would come to an end soon. If markets are informationally efficient, firms that profit from the free allowance system should then see a decrease of their stock price through similar expected cash flow and discount rate effects as for the CBAM. In the rest of the paper, we will refer to this as the "free allowances treatment". It operates at the intensive margin. Note that for the EU ETS, it is the producers within the EU which have to purchase the emission certificates, not the customers. But again, depending on the bargaining power, we may still see a stock price response for customers as well.

Concerning (2), a similar signaling effect may exist with respect to goods that are not subject to the CBAM initially. The press release on Dec 13, 2022, announced the commitment to include all goods covered by the ETS by 2030. If markets are efficient, most firms which import ETS-regulated goods into the European Union should see a decrease in their stock price upon announcement of the CBAM decision. Market participants should update their beliefs, which will have repercussions on stock prices through expected cash flows and discount rates again. We will refer to this as the "CBAM extension treatment".

3 Data and Methodology

3.1 Data

We merge seven datasets for our analysis. The central datasource for our study is the FactSet Revere Supply Chain Relationships Database, which provides details on business relations between companies worldwide, for instance information on suppliers, customers, competitors or strategic partners. This information is systematically collected from primary public sources such as SEC 10-K annual filings, investor presentations, and press releases, and classified according to normalized relationship types. We start from the 729,223 global customer-supplier relationships that are active in the time period between January 01, 2021 and February 23, 2024. We then restrict the sample to relationships which are active around the event date (i.e. with start date before and end date after December 13,2022), which results in 321,268 active relationships. These active relationships involve 70,827 customer firms and 28,910 supplier firms globally.

Most data on firm characteristics such as firms' location, industry, stock price (including the adjustment factor accounting for dividend payments) is taken from Compustat North America and Global. As many small supplier firms are not publicly listed, we complement the data with location data from FactSet and suppliers' primary 4-digit SIC as well as 8 other non-primary SICs from Worldscope. For our study, it is paramount to consider all available SIC codes because a firm which produces diverse goods in different industries can be affected by the CBAM even if its core products are not subject to it. The firm-level data is matched via FactSet IDs as well as ISIN and SEDOL numbers. After merging with suppliers' location and industry information, we are down to 65,038 global customers and 20,154 global suppliers.

The EU CBAM legislation specifies only goods categories to be subject to the border tax, not entire industries. To divide customers and suppliers into treatment and control group, we therefore need to link our industry information with goods categories. The list of affected goods is taken from the Official Journal of the European Union (L 130, published on May 16, 2023). The provisional agreement between the European Parliament, the European Commission and the European Council that was reached on December 13, 2022, states that the CBAM will initially apply to imports of cement, iron and steel, aluminium, fertilisers, electricity and hydrogen, whose production is very carbon intensive and presumably at the most significant risk of carbon leakage. The goods are listed with their official CN codes. We use the linking table provided by Pierce and Schott (2012)¹² in order to match the CBAM-affected goods (CN or HS codes) to industries (SIC codes). We use 6-digit CN or HS codes for the matching. Out of the 1,036 SIC codes in our sample, 474 appear in the linking table. As a result, our sample is reduced to 15,471 customers and 5,178 suppliers globally. Since our analysis focuses on customers located within the EU and suppliers inside or outside the EU, our final data sample contains 1,142 publicly listed EU customers and their suppliers.

We calculate cumulative abnormal returns (CARs) of European customers using the daily European asset pricing factors provided by Ken French¹³, which represents the conventional way to control for confounding factors in cross-sectional asset pricing. We are interested in the stock price response to our event which goes above and beyond the variation caused by a firm's exposure to the standard systematic risk factors (market return, size, value, profitability and investment), which have been shown to be major drivers of the cross-section of equity returns. To compute the CARs of global suppliers, we proxy the market excess returns through the difference between returns of country-level MSCI equity indices and 1-month sovereign zero-coupon rates. This data is downloaded from Thomson Reuters Eikon.

3.2 Methodology

We study the stock market responses to the introduction of the CBAM via event studies. To do so, we first calculate the daily abnormal log return $AR_{i,t}$ relative to the CAPM.¹⁴ Market betas are based on 180 days prior to the event window. The cumulative abnormal return, $CAR_{i,t-2,t+2}$,

¹²The linking table is available on the webpage of Peter Schott: https://sompks4.github.io/sub_data.html.

¹³See https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html.

¹⁴We consider the Fama French 3-factor and 5-factor models in robustness checks further below.

for each customer is defined as the sum over all $AR_{i,t}$ over the five-day event window. We then compare the average CARs of various groups of firms.

There are a lot of possible ways to split the sample into treatment and control groups. We will later present results from a series of robustness checks for the choices that we make in this regard. In our baseline analysis, we study only the CARs of European customer firms because they are more relevant for policymakers within the EU. We will later, in Section 4.2, also discuss results for supplier firms, but because of sampling issues these results need to be taken with a grain of salt.

Our baseline exercise for EU customer firms is specified as follows. A customer firm that is supposed to be treated by the CBAM must have at least one supplier which satisfies two requirements: (i) the supplier is located outside the EU and (ii) it supplies goods that fall under the CBAM-affected goods categories.

In order to operationalize requirement (i), we construct the variable *loc_treat_ratio*, defined as the number of non-EU suppliers divided by the total number of suppliers for each customer:

$$loc_treat_ratio_i = \frac{\# \text{ non-}EU \text{ suppliers of firm } i}{\# \text{ suppliers of firm } i}.$$

For requirement (ii), we need to make additional assumptions on the link between industries and goods. We define an industry as CBAM-affected if at least one type of goods produced by this industry (according to the industry-goods linking table) falls under the CBAM. Furthermore, we define a supplier as CBAM-affected if it belongs to at least one affected industry (according to its primary and non-primary SIC codes). We then construct the variable *ind_treat_ratio*, defined as the number of suppliers in CBAM-affected industries divided by the total number of suppliers for each customer:

$$ind_treat_ratio_i = rac{\#suppliers \ of \ firm \ i \ in \ CBAM-affected \ industries}{\# \ suppliers \ of \ firm \ i}.$$

We categorize firms into treatment and control groups based on these two treatment variables. The control group in the following consists of all customer firms for which both $loc_treat_ratio_i$ and $ind_treat_ratio_i$ are equal to zero, i.e., firms which have no suppliers outside the EU and no suppliers in treated industries. Because the number of firms in the control group is rather small, we will also show results for a broader control group comprising firms for which both $loc_treat_ratio_i$ and $ind_treat_ratio_i$ are below the cross-sectional median. We will label this group as "generalized control group". The treatment group contains all firms for which both $loc_treat_ratio_i$ and $ind_treat_ratio_i$ are above the cross-sectional median.

Ideally, we would like to extend the control group to also include firms for which only one of the two requirements is satisfied, but not both. At first glance, these firms should also be unaffected by the CBAM. However, as the discussion in Section 2.2 has shown, they may be subject to ancipatory treatment effects regarding broader climate policy changes. We therefore handle these firms separately. To address the beliefs updating hypotheses, we will construct several other treatment groups using combinations of the variables *loc_treat_ratio_i* and *ind_treat_ratio_i*, which we introduce as we go along. Finally, we will present a series of robustness checks where we vary the composition of treatment and control groups further.

	(1)	(2)	(3)
	Control	Generalized	Treatment
	group	control group	group
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i < median \ \& \\ ind_treat_ratio_i < median \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$
ln(MktCap)	17.8934	18.3503	19.7996
Inverse Price	0.4287	0.6527	0.3017
Amihud Ratio	1.1233	1.0063	0.0771
Bid-ask Spread (%)	0.0274	0.0287	0.0274
$\ln(Assets)$	20.6224	21.2722	22.6977
Debt/Assets	0.2959	0.2811	0.2705
PP&E/Assets	0.3103	0.2584	0.2268
EBIT/Assets	-0.0226	0.0051	0.0573
Capex/Assets	0.0567	0.0421	0.0394
# Observations	117	354	209

Table 2: Stock and Firm Characteristics

Table 2 reports the mean of stock and firm characteristics for (generalized) control and treatment group. To avoid forward-looking bias, we use the balance sheet and financial data as of the end of 2021.

Table 2 reports a few summary statistics for our treatment and control groups. The firms in the treatment group all have international supply chains by construction. Not surprisingly, they are larger and more profitable than the firms in the control group. Following standard practice in asset pricing, we control for these differences in robustness checks (see Section 6.4) where we construct cumulative abnormal returns relative to the Fama-French five factor model. All our results are robust. The stocks of firms in the treatment group are also more liquidly traded. But the stocks in the control group are far away from being illiquid, as indicated by the bid-ask spread, for instance. In particular, our key treatment effects reported below are orders of magnitude larger than the bid-ask spread. For completeness, Table A.1 in Appendix A shows the sectoral composition of our treatment and control groups. Importantly, our sample of EU customer firms covers a broad and representative range of manufacturing sectors. It thus includes various sectors for which the introduction of the CBAM can be expected to have a meaningful effect.

4 Results

4.1 Total treatment effect for customers inside the EU

This section presents the results from our baseline exercise. Table 3 reports the average cumulative abnormal returns of the treatment group and the two control groups around the event date (December 13, 2022). The stars indicating statistical significance are derived from two-sided t-tests of the null hypothesis that the respective mean equals zero. Table 3 also reports the differences of the average CARs between the groups, together with the p-value from a one-sided t-test of the null hypothesis that these differences in mean are positive or zero.¹⁵ Complementing Table 3, Figure 1 depicts the evolution of the cumulative abnormal returns over the event window. The last datapoint that is plotted in Figure 1 is identical to the CAR of the respective group reported in Table 3.

The treatment group exhibits a strongly negative return, which is both statistically significant and economically large (-1 percentage point on average). The net treatment effect of -1.3 percentage points is also strongly significant. When we use the generalized control group as a

¹⁵We rely on one-sided t-tests following the discussion about testable hypotheses outlined in Section 2. Eventually, we seek to analyze whether the introduction of the CBAM had a negative effect on stock returns of regulated firms.

	(1)	(2)	(3)	(4)	(5)
	Control	Generalized	Treatment	Difference	Difference
	group	control group	group	(3) - (1)	(3) - (2)
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i < \text{median } \& \\ ind_treat_ratio_i < \text{median} \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$		
Mean CAR	0.0035	0.0000	-0.0097***	-0.0131***	-0.0096**
SE	(0.0036)	(0.0030)	(0.0030)		
p-value				(0.0036)	(0.0164)
# Obs	117	354	209		

Table 3: Total treatment effect

Table 3 reports the average CARs for the treatment group and the two control groups of EU customer firms for the 5-day event window around December 13, 2022. The treatment group comprises customers with above median *loc_treat_ratio* and above median *ind_treat_ratio*. The control group comprises firms with *loc_treat_ratio* = 0 and *ind_treat_ratio* = 0. The generalized control group comprises firms where both ratios are below the median. The variable *loc_treat_ratio* is defined as the number of non-EU suppliers divided by the total number of suppliers for each customer. The variable *ind_treat_ratio* is defined as the number of suppliers in CBAM-affected industries divided by the total number of suppliers for each customer. Robust standard errors or p-values are reported in parentheses. CARs are calculated relative to CAPM expected returns. In the first three columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the last two columns, they refer to a one-sided t-test of the null hypothesis of the mean difference being positive or zero. comparison, the treatment effect becomes slightly smaller, but remains significant.

Supporting our causal interpretation, Figure 1 reveals that the bulk of this negative return is in fact realized during a narrow two-day window around the event date. To be precise, all returns in our analysis are obtained from closing prices. The press release about the breakthrough in the negotiations was published at 1:00 a.m. in the morning on Tuesday, December 13, 2022. The final round of negotiations itself took place over the course of Monday, December 12, 2022. Acknowledging the possibility of information leakage during such political bargaining, it seems natural that stock prices already started reacting at some point between market close on Friday, December 09, 2023, and market close on Monday, December 12, 2023.




Figure 1: Total treatment effect

Figure 1 depicts the average CARs for the same groups as in Table 3 over the 5-day event window around December 13, 2022. The last datapoint in each plot is identical to the CAR of the respective group reported in Table 3. CARs are calculated relative to CAPM expected returns. The vertical lines on each day indicate 95% confidence intervals based on robust standard errors.

Altogether, we view this as clear evidence that the introduction of the CBAM affects the market valuation of EU customers with treated suppliers negatively. Albeit quantitatively small at first glance, the size of the treatment effect is remarkable. Importantly, it can be considered a lower bound for the total effect of the CBAM on the stock prices of treated firms. This is because our event date is only one in a long sequence of dates where news about the CBAM was released, and most of these news indicated that the CBAM could become stricter than

previously expected. As outlined in Section 2, a lot of these news releases unfortunately fall together with news about other parts of the "Fit for 55 package", so that they are not suitable for clean identification in an event study. Presumably, the total effect of the CBAM on stock prices is thus much larger than documented in the table.

Finally, we have also looked into various subsamples, for instance along the lines of a sectoral decomposition. Since our sample size is relatively small, we do not find statistically significant treatment effects in such subsamples. Therefore we do not report any numbers in our paper. However, the point estimates for sectoral subsamples are mostly in line with the economic rationale concerning the policy announcement on December 13, 2022. For instance, we observe a (statistically insignificant) treatment effect of -3 percentage points for the cement industry, potentially caused by the surprising negotiation outcome that the CBAM will also cover Scope 2 emissions from cement production. Similarly, we observe no treatment effect at all for the food manufacturing industry, confirming the intuition that the announcement did not contain any news regarding the inclusion of agricultural upstream products like fertilizers into the CBAM. More details are available upon request.

4.2 Cumulative abnormal returns of suppliers

In our baseline specification above, we analyze the stock returns of customer firms inside the EU only. Obviously, supplier firms both inside and outside the EU are affected by the CBAM regulation as well. Unfortunately, we have only limited data available to derive robust results for the cumulative abnormal returns of suppliers. There are several reasons for this. First, many supplier firms in our customer-supplier relationship data are small and not publicly listed. Second, we are dealing with a very heterogeneous international sample of firms, which complicates the computation of cumulative abnormal returns relative to the CAPM. We use MSCI country-level equity indices as proxies for the market factor, acknowledging that there remains a lot of noise in the abnormal returns. Third, the international sample of firms which have customer-supplier relationships reported in our data is rather small and cannot be regarded as representative for the worldwide set of publicly listed firms. In particular the cumulative abnormal returns of what we label as control group have to be taken with a grain of salt.

	(1)	(2)	(3)
	Control	Treatment	Difference
	group	group	(2) - (1)
	$\begin{array}{l} EU_customer_ratio_{j} > 0 \\ \& \ ind_cbam_{j} = 0 \end{array}$	$\begin{array}{c} EU_customer_ratio_{j} > 0 \\ \& \ ind_cbam_{j} > 0 \end{array}$	
Mean CAR	-0.0567***	-0.0802***	-0.0235
SE	(0.0117)	(0.0150)	
p-value			(0.2859)
# Obs	662	53	

Table 4: Cumulative abnormal returns of non EU suppliers

Table 4 reports the average CARs for groups of supplier firms outside the EU for the five-day event window around December 13, 2022, as well as differences between them. CARs are calculated relative to CAPM expected returns. The composition of the different groups is explained in Section 4.2. Robust standard errors or p-values are reported in parentheses. For the CAR of each group, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. For the CAR differences, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

Despite the caveats concerning data quality indicated above, we essentially follow the same event study procedure as in the previous section. In the final dataset, we have identified 1,598 publicly listed suppliers which are located outside the EU. We construct the variable $EU_customer_ratio$, defined as the number of EU customers divided by the total number of customers for each supplier:

$$EU_customer_ratio_j = \frac{\# \ EU \ customers \ of \ supplier \ j}{\# \ customers \ of \ supplier \ j}.$$

As in the baseline specification, we define an industry as CBAM-affected if at least one type of goods produced by this industry (according to the industry-goods linking table) falls under the CBAM. The dummy variable ind_cbam_j equals 1 if supplier j belongs to at least one affected industry (according to its primary and non-primary SIC codes) and 0 otherwise.

The most suitable control group for this exercise comprises supplier firms outside the EU which have customers within the EU, but in different industries that are not subject to the CBAM. The group labeled as "control group" in the following thus refers to firms which have $EU_customer_ratio > 0$, but $ind_cbam = 0$. The "treatment group" comprises all firms which have EU customers and belong to CBAM-affected industries ($EU_customer_ratio > 0$, and

 $ind_cbam = 1$).¹⁶

The results for the cumulative abnormal returns of supplier firms outside the EU are presented in Table 4.¹⁷ In line with the results for customer firms, the treatment group has the most negative cumulative abnormal return. The difference between the treatment and the control group amounts to -2 percentage points and is thus even larger than the treatment effect that we have measured for customer firms in Section 4.1. Unfortunately, because of the large noise in the data, the difference is statistically insignificant. But, as we show in robustness checks in Section 6.5 later on, there are also slightly different specifications of treatment and control groups in which the negative treatment effects for suppliers become significant. Moreover, because of the data limitations outlined above, the control group has a large negative and significant CAR as well, reflecting the fact that our control group is not representative for the worldwide universe of publicly listed firms. Still, altogether, we view these results as roughly confirming the results for customers presented in the previous section, but take them with a grain of salt.

4.3 Further event dates

For completeness, we report cumulative abnormal returns for EU customer firms for a set of further events outlined in Section 2. These events are unfortunately characterized by news about several different EU climate policies being announced jointly on one day, making causal identification impossible at first glance. But we can still gain some insights from the following results. Specifically, none of the other policy measures of the "Fit for 55 package" that were negotiated in parallel with the CBAM, like a reform of the EU ETS, are directly related to international trade. We can thus still meaningfully compare different treatment groups with each other. It is rather the firms in the control group that are affected by several policy measures at the same time. For this reason, we try not to overinterpret any numbers for the control group in the following.

The event study is designed exactly as in the baseline specification. We study three addi-

¹⁶The median of $EU_customer_ratio$ equals zero, rendering a median split like in the previous section infeasible. In a robustness check also reported below, we split the sample into control and treatment groups along the 70% of the cross-sectional distribution of the $EU_customer_ratio$, i.e. we compare firms below the 70% quantile and firms above the 70% quantile.

¹⁷The complete results of non EU suppliers are documented in Table B.2 in Appendix B.

tional dates. On July 14, 2021, the EU Commission presented the initial proposal for the CBAM, along with proposals for several other climate policy measures subsumed under the "Fit for 55 package". Around this date, we have 278,145 active customer-supplier relations, and we end up with 1,140 EU customers after merging with the various other databases. On February 09, 2023, the Parliamentary Committee of the Environment, Health, and Food Safety adopted the final Trilogue agreement. There we have 332,037 active customer-supplier relations and end up with 1,130 EU customers. On April 18, 2023, the EU Parliament finally adopted the CBAM regulation. For this event, we have 568,926 active customer-supplier relations and 1,120 EU customers.¹⁸

Table 5 presents the results for all three dates. For the sake of readability, we report only the numbers for the total treatment, the complete set of results can be found in Table B.3 in Appendix B. Several observations can be made. First of all, there is no treatment effect at all on February 09, 2023. We view this as evidence that all relevant news related to the Trilogue agreement have been priced in since the press release on December 13, 2022. The publication of the full text of the regulation two months later does not trigger any stock price reaction.

Second, both the release of the first proposal by the EU Commission on July 14, 2021, and the final decision by the EU Parliament on April 18, 2023, trigger large (but insignificant) stock price reactions. We avoid to interpret the numbers for the control group because of the simultaneity of several policy announcements. But this concern of non-separability does not apply to the location treatment in isolation. In fact, the complete set of results in the appendix suggests that the partial treatments (both location and industry) also give rise to large negative (but insignificant) stock returns of up to -0.8 percentage points around July 14, 2021. For April 18, 2023, the respective treatment effects are even larger (up to -2.4 percentage points).

Taken together, these numbers give a very rough indication of the economic significance of the CBAM for financial markets. Of course, adding up the treatment effects around all the different dates is statistically infeasible. For one, they are derived from very different samples.

¹⁸As discussed in Section 2, the list of goods that are subject to the CBAM varies across the event dates. For instance, the initial list that comes with the proposal on July 14, 2021, comprises fewer goods than the final CBAM regulation on April 18, 2023. We therefore use different lists of goods, exactly as published on the respective event dates, throughout this section.

		(1)	(2)	(3)
		Control	Treatment	Difference
Event date		group	group	(2) - (1)
		$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$	
	Mean	0.0024	-0.0116	-0.0140
July 14, 2021	SE	(0.0050)	(0.0091)	
	p-value			(0.1047)
	#Obs	151	191	
	Mean	0.0035	-0.0097***	-0.0131***
Dec 13, 2022	SE	(0.0036)	(0.0030)	
	p-value			(0.0036)
	#Obs	117	209	
	Mean	0.0011	-0.0035	-0.0046
Feb 9, 2023	SE	(0.0040)	(0.0043)	
	p-value			(0.2429)
	#Obs	112	216	
	Mean	0.0007	-0.0175	-0.0182
April 18, 2023	SE	(0.0049)	(0.0186)	
	p-value			(0.2620)
	#Obs	118	247	

Table 5: Average CARs on other event dates

Table 5 reports the average CARs for each group of EU customer firms for five-day event windows around a few other event dates. CARs are calculated relative to CAPM expected returns. The control and treatment groups are defined in the same way as in Tables 3. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the third column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

For another, we cannot control for other, potentially positive or zero news reaching the market in between the events. Still, from our reading of the sequence of legislative documents published by the EU decision-making bodies over the course of two years, there was not much contrarian positive or zero news along the negotiation process of the CBAM which could have reversed the negative treatment effects that we find. Specifically, the opinions of both the European Parliament and the Council of the European Union can be regarded as stricter than the initial proposal by the EU Commission, and so was the final outcome of the Trilogue. The (hypothetical, back-of-the-envelope) combined treatment effect for EU customers across the three major event dates (July 14, 2023, December 13, 2022, and April 18, 2023) amounts to more than 4 percentage points. On top, the analysis of supplier firms in Section 4.2 suggests that the treatment effects for suppliers outside the EU could be (at least) about equally large. Against the background of economic debates about "stranded assets" resulting from the tightening of climate policies, these numbers are remarkable.

5 Updating beliefs about climate policy changes

The timeline of the policy process discussed in Section 2 has revealed that the agreement about the CBAM on December 13, 2022, was only part of a larger package of legislations that were negotiated in parallel. Thus, market participants may have perceived the CBAM agreement as a signal that the negotiations about the other parts of this package would soon come to a successful end as well. The most important companion legislation is the phasing-out of free allowances under the EU ETS, on which the different parties in fact reached an agreement a few days later. Moreover, as another surprise, the press release about the CBAM on December 13, 2022, states the explicit goal of the EU to extend the CBAM to all goods covered by the EU ETS until 2030.

If markets are informationally efficient, the updating of beliefs about climate policy reforms should change market prices immediately, as soon as the signal becomes public. Our setup of treatment and control groups allows us to test this hypothesis. Specifically, we study a set of treatment groups that can be seen as intermediate cases between the CBAM treatment and control groups analyzed above. Remember that a customer firm that is supposed to be treated by the CBAM must have at least one supplier which satisfies two requirements: (i) the supplier is located outside the EU and (ii) it supplies goods that fall under the CBAM-affected goods categories. In the following, we construct groups of firms that satisfy only one of the two requirements.

For instance, firms which purchase CBAM-affected goods, but from producers inside the EU, are most likely affected by the phasing-out of free allowances. This is because the key reason for the existence of free allowances under the EU ETS has been the missing carbon price for the respective goods outside the EU. Without the CBAM and without free allowances, firms importing from outside the EU have a comparative advantage relative to their peers. The CBAM is supposed to close this loophole. In order to level the playing field (and to comply with WTO rules), the free allowances for these respective goods must be phased out in parallel with the introduction of the CBAM.

The CBAM announcement on Dec 13, 2024, may also induce a beliefs update about a potential broadening of the CBAM to cover further goods categories. Specifically, the CBAM announcement came with the commitment that the EU will examine such a broadening until 2030. Firms which import non-CBAM-affected goods from producers outside the EU are most likely affected by this extension.

Tables 6 and 7 report the CARs for the respective treatment groups and some more differences across groups. Figures 2 and 3 present the respective returns of these groups over the full event window.¹⁹

5.1 Phasing out of free allowances

Table 6 addresses the issue of the phasing-out of free allowances under the EU ETS and presents results from a treatment based on suppliers' industries. We compare the control group from Table 3 with a group that comprises firms with above median *ind_treat_ratio*, but below median *loc_treat_ratio*. Stated differently, the EU customer firms in this group have many suppliers in

¹⁹For the sake of readability, we do not report the CAR differences between all possible combinations of groups in the tables and figures here. The complete set of results is reported in Table B.1 in Appendix B.

CBAM-treated industries, but mostly from within the EU. This group comprises firms which are most likely to be affected by a reduction in free allowances under the EU ETS. The treatment effect is negative, significant, and economically large, exceeding -1 percentage point. Moreover, from Figure 2, we again take away that the bulk of this treatment effect is realized in a very narrow time window around the event. On the other hand, the treatment effect in Table 6 is somewhat smaller than the treatment effects in our baseline analysis of the CBAM effect in Table $3.^{20}$

Taken together, the information on suppliers' industries has a substantial negative impact on EU customer returns, irrespective of the location of these suppliers and whether they are actually subject to the CBAM. We view these results as evidence that market participants perceived the announcement of the Trilogue agreement concerning the CBAM as a signal that a Trilogue agreement concerning the phasing-out of free allowances was to follow soon and that they updated their beliefs accordingly.

Importantly, we have also run our event study around December 18, 2022, the day when the Trilogue agreement concerning the free allowances was reached. We do not find any significant stock price reactions there. While insignificant results should always be interpreted with care, we still view the absence of any market response as an indication that the new information was largely priced in already one week earlier.

5.2 Extension of the CBAM

Table 7 addresses the issue of a possible extension of the CBAM to all goods that are currently regulated by the EU ETS. It presents results from two additional treatments based on suppliers' location inside versus outside the EU. For Panel A, we simply perform a median split based on the variable *loc_treat_ratio*. I.e., we compare EU customer firms with many suppliers outside

 $^{^{20}}$ We wish to point out that – in principle – an analysis of the anticipation effects for EU ETS reforms should rather focus on supplier firms within the EU. This is because the suppliers are the firms who currently receive the free allowances and who will have to pay for the EU ETS certificates in the future. Unfortunately, within our dataset, we do not have enough observations of publicly traded supplier firms for this type of analysis. Therefore we stick to the customer firms in our sample. If the additional burden from having to purchase EU ETS certificates spills over, there should also be an effect on asset prices for these firms, and in fact our results confirm this hypothesis.

	(1)	(2)	(3)
	Control	Industry treatment,	Difference
	group	location control group	
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i < median \ \& \\ ind_treat_ratio_i > median \end{array}$	
Mean	0.0035	-0.0069***	-0.0104*
SE	(0.0036)	(0.0025)	
p-value			(0.0088)
#Obs	117	217	

Table 6: Free allowances treatment effect

Table 6 reports the average CARs for further groups of EU customer firms for the five-day event window around December 13, 2022. The treatment group comprises customers with below median *loc_treat_ratio* and above median *ind_treat_ratio*. The CAR of the control group has been reported in Table 3. Robust standard errors or p-values are reported in parentheses. CARs are calculated relative to CAPM expected returns. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. For the differences in the last column, the stars refer to a one-sided t-test of the null hypothesis of the mean difference being positive or zero.






Figure 2 depicts the average CARs for the control group and the industry treatment, location control group over the 5-day event window around December 13, 2022. The groups are the same as those in Table 6. CARs are calculated relative to CAPM expected returns. The vertical lines on each day indicate 95% confidence intervals based on robust standard errors.

the EU with EU customers which have only few suppliers outside the EU, irrespective of the industry of these suppliers. Interestingly, we observe a negative and significant treatment effect of about -0.5 percentage points, i.e. about half as large as the total treatment effect shown in the Section 4.1.

	Panel A: Only	location information	
	(1)	(2)	(3)
	Location	Location	Difference
	control group	treatment group	
	$loc_treat_ratio_i < {\rm median}$	$loc_treat_ratio_i > \mathrm{median}$	
Mean CAR	-0.0027	-0.0081***	-0.0054*
SE	(0.0021)	(0.0031)	
p-value			(0.0724)
# Obs	571	571	
]	Panel B: Location (1)	and industry information (2)	on (3)
	Control	Location treatment,	Difference
	group	industry control group	1
	$loc_treat_ratio_i = 0 \&$	$loc_treat_ratio_i > median \&$	

Table 7:	CBAM	extension	treatment	effect

Panel B: Location and industry information			
	(1)	(2)	(3)
	Control	Location treatment,	Difference
	group	industry control group	
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i < \text{median} \end{array}$	
Mean CAR	0.0035	-0.0072	-0.0106*
SE	(0.0036)	(0.0045)	
p-value			(0.0982)
# Obs	117	362	

Table 7 reports the average CARs for further groups of EU customer firms for the five-day event window around December 13, 2022. The location treatment group and location control group in Panel A result from a median split of our entire sample for the variable loc_treat_ratio. The treatment group in Panel B comprises customers with below median *ind_treat_ratio* and above median loc_treat_ratio. It is a subgroup of the location treatment group in Panel A. The CAR of the control group in Panel B has been reported in Table 3. Robust standard errors or p-values are reported in parentheses. CARs are calculated relative to CAPM expected returns. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. For the differences in the last column, the stars refer to a one-sided t-test of the null hypothesis of the mean difference being positive or zero.

The official CBAM regulation contains the commitment that, by 2030, all goods that are subject to the EU ETS should also be subject to the CBAM. Even though the official CBAM regulation concentrates on a few selected goods initially, investors may thus anticipate many more goods (or industries, respectively) to be subject to the CBAM in the future, as long as the suppliers are located outside the EU. If markets are informationally efficient, this updating of beliefs should affect prices immediately, and this is what our results document.

In Panel B, we view the CBAM extension treatment effect from another angle, supporting these explanations. Specifically, we compare the control group, which was already presented in Table 3, with another dedicated group. This group comprises firms with above median *loc_treat_ratio*, but below median *ind_treat_ratio*.²¹ Stated differently, the EU customer firms in this group have many suppliers outside the EU, but mostly in industries that are currently not subject to the CBAM, however, may be affected in the future. This group is a subgroup of the location treatment group in Panel A. The treatment effect is again negative, significant, and economically large, exceeding -1 percentage point. Figure 3 also indicates that the bulk of this treatment effect is indeed realized in a very narrow time window around the event. Altogether, we view these results as evidence that the announcement that the CBAM is likely going to be expanded by 2030 has significant effects on the stock prices of firms which may arguably be affected by this additional policy reform in the future.

As a final exercise, Table B.4 in the Appendix reports the treatment effect when we bunch all three treatment groups (double treatment, location treatment and industry treatment) together into one "universal treatment group". This group combines all firms which are supposedly affected by the CBAM regulation, either directly through the carbon border payments or indirectly through a phasing-out of free allowances or through the expectation of being subject to the CBAM in the future. The universal treatment effect amounts to -1.12 percentage points and is strongly statistically significant.

6 Robustness

We close the paper with a series of robustness checks concerning choices that we made for our baseline specification. For the sake of readability, we only report a small selection of the

²¹In contrast to the control group, we do not impose the stricter condition $loc_treat_ratio_i = 0$ here because this would reduce the number of firms in the treatment group considerably. The same holds true for Table 6 above.




Figure 3: CBAM extension treatment effects

Figure 3 depicts the average CARs for different treatment groups over the 5-day event window around December 13, 2022. The treatment groups are the same as those in Table 7. CARs are calculated relative to CAPM expected returns. The vertical lines on each day indicate 95% confidence intervals based on robust standard errors.

cumulative abnormal returns in the main text. The complete set of results can be found in Tables B.5 to B.8 in Appendix B.

6.1 Longer event window

Table 8 reports cumulative abnormal returns around December 13, 2022, when we extend the event window to 10 days, ranging from December 08 to December 20. Figure 4 displays the returns graphically. First of all, this robustness check confirms that the parallel trends assumption, which underlies any diff-in-diff event study, holds. Second, over this longer event window, the cumulative abnormal return of the treatment group is much more negative than in the baseline exercise, exceeding -2.7 percentage points. However, the control group also exhibits a strongly negative (but insignificant) return. As a result, the treatment effect is insignificant and smaller than in the baseline setting. Notably, when we compare the treatment group to the generalized control group as defined in Table 3 (results not shown here for brevity), the treatment effect turns out to be significant again and exceeds -1 percentage point.

Importantly, the extended 10 trading days event window includes Sunday, December 18,




Figure 4: Robustness check: longer event window

Figure 4 depicts the average CARs for each group of EU customer firms for the 10-day event window around December 13, 2022. The treatment groups are the same as those in Sections 4.1 and 5. CARs are calculated relative to CAPM expected returns. The vertical lines on each day indicate 95% confidence intervals based on robust standard errors.

	(1)	(2)	(3)
	Control	Treatment	Difference
	group	group	(2) - (1)
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$	
Mean	-0.0215	-0.0271***	-0.0056
SE	(0.0118)	(0.0054)	
p-value			(0.3119)
#Obs	117	209	

Table 8: 10 day event window

Table 8 reports the average CARs for each group of EU customer firms for the 10-day event window around December 13, 2022. The composition of the different treatment groups is the same as in Tables3. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the third column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

2022, the day when the Trilogue agreement about the phasing out of free allowances under the EU ETS was officially announced. The figure shows that this conflicting climate policy event did not induce another major shift in stock prices for any of the treatment groups. The primary source for the blurred results over the longer time window is the large standard error for the control group, not the potential response to the follow-up announcement. We interpret this as corroborating evidence that the announcement of December 18, 2022, was already anticipated. The news were already priced in by market participants after our main event date, December 13, 2022.

Taken together, we view the strong negative abnormal return of the treatment group as evidence that our findings are, with a grain of salt, robust to extending the event window. But the additional news that arrive on financial markets during this longer event window make it harder to identify a clear treatment effect.

6.2 Alternative specifications of treatment and control groups

Table 9 reports cumulative abnormal returns around December 13, 2022, when we slightly change the specification of treatment and control groups. Instead of median splits for the two treatment variables $loc_treat_ratio_i$ and $ind_treat_ratio_i$, we now split the sample at the 70% quantile or at the 30% quantile of the respective cross-sectional distributions.

		(1)	(2)	(3)
		Control	Treatment	Difference
		group	group	(2) - (1)
		$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\label{eq:loc_treat_ratio_i} \begin{split} loc_treat_ratio_i > \mathbf{x}\% \text{ quantile } \& \\ ind_treat_ratio_i > \mathbf{x}\% \text{ quantile} \end{split}$	
70% quantile	Mean	0.0035	-0.0055	-0.0090*
split	SE	(0.0036)	(0.0061)	
	p-value			(0.0899)
	$\# \ \mathrm{Obs}$	117	80	
30% quantile	Mean	0.0035	-0.0084**	-0.0119***
split	SE	(0.0036)	(0.0023)	
	p-value			(0.0035)
	$\# \ \mathrm{Obs}$	117	306	

Table 9: Alternative specifications of treatment and control groups

Table 9 reports the average CARs for each group of EU customer firms for the five-day event window around December 13, 2022. The composition of groups is similar as in Tables 3, but the different treatment groups are based on 70% or 30% quantile splits, respectively. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the third column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

The average cumulative abnormal returns of the different groups are hardly affected by these choices. We mainly see changes in the p-values for the CAR differences for some of the partial treatments (not reported here for brevity). Qualitatively, our results are very robust.

6.3 Customer-supplier relationships ending prior to the event date

One may be concerned that the information about the start and end date of a customer-supplier relationship which firms disclose in official declarations and which is then incorporated into the FactSet Supply Chain database is not equal to the true beginning or end of the relations among these firms. FactSet mainly relies on official SEC 10-K annual filings. But customer-supplier relationships may, e.g., be paused and resumed later on, or it may take some time to negotiate contracts and build up a new relationship. Such processes are not fully captured in the SEC 10-K repository, which takes into account only realized and reported sales of goods from one firm to another.

		(1)	(2)	(3)
		Control	Treatment	Difference
		group	group	(2) - (1)
		$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$	
1 month	Mean	0.0034	-0.0099***	-0.0133***
	SE	(0.0036)	(0.0030)	
	p-value			(0.0031)
	# Obs	118	213	
2 months	Mean	0.0039	-0.0097***	-0.0135***
	SE	(0.0035)	(0.0021)	
	p-value			(0.0025)
	$\# \ \mathrm{Obs}$	117	220	
3 months	Mean	0.0053	-0.0091***	-0.0144***
	SE	(0.0035)	(0.0029)	
	p-value			(0.0012)
	$\# \ \mathrm{Obs}$	119	221	

Table 10: Relationships ending prior to event date

Table 10 reports the average CARs for each group of EU customer firms for the five-day event window around December 13, 2022. The composition of groups is similar as in Tables 3, but we allow the customer-supplier relationships to end 1, 2, 3 months before the event date. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the third column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

We therefore run robustness checks where we also include customer-supplier relationships that have officially been terminated 1, 2, or 3 months prior to our main event date. This increases our sample size only very slightly to 1,148, 1,157, or 1,167 EU customer firms, respectively. Table 10 reports the cumulative abnormal returns. They are practically identical to those in the baseline specification.

6.4 Fama-French three-factor and five-factor model

The one-factor Capital Asset Pricing Model is arguably a very rough model when it comes to computing abnormal returns for a cross-section of stocks. For robustness, we estimate our baseline specification using the Fama-French three-factor or five-factor model instead. For our sample of EU customer firms, we use the European Fama-French factors that are available on Kenneth French's webpage, although these factors also contain information from stocks traded in some non-EU countries like the UK.

		(1)	(2)	(3)
		Control	Treatment	Difference
		group	group	(2) - (1)
		$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i > \text{median } \& \\ ind_treat_ratio_i > \text{median} \end{array}$	
FF3	Mean	-0.0002	-0.0109***	-0.0108**
	SE	(0.0035)	(0.0037)	
	p-value			(0.0277)
	# Obs	117	209	
FF5	Mean	-0.0006	-0.0119***	-0.0113**
	SE	(0.0036)	(0.0033)	
	p-value			(0.0151)
	# Obs	117	209	

Table 11: Average CARs with respect to FF3 and FF5 factors

Table 11 reports the average CARs with respect to the Fama-French three-factor and five-factor models for each group of EU customer firms for the five-day event window around December 13, 2022. The composition of the different treatment groups is the same as in Tables3. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the third column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

The results are presented in Table 11. Qualitatively, our results remain unchanged. In fact, the average cumulative abnormal return of the treatment group is now slightly more negative, the CAR of the control group is now virtually zero, and the total net treatment effect is about the same size as in baseline specification.

6.5 70% split for supplier firms

Finally, we present results from a robustness check regarding the analysis of the returns of supplier firms in Section 4.2. There, we sorted firms with $EU_customer_ratio_j = 0$ into the control or industry treatment group and firms with $EU_customer_ratio_j > 0$ into the treatment

or location treatment group.

	(1)	(2)	(3)
	Control	Treatment	Difference
	group	group	(2) - (1)
	$EU_customer_ratio_j > 70\%$ quantile & $ind_cbam_j = 0$	$\begin{array}{l} EU_customer_ratio_{j} > 70\% \text{ quantile} \\ \& \ ind_cbam_{j} > 0 \end{array}$	
Mean CAR	-0.0559***	-0.0968***	-0.0409
SE	(0.0171)	(0.0183)	
p-value			(0.2455)
# Obs	439	37	

Table 12: Cumulative abnormal returns of non EU suppliers (70% split)

Table 12 reports the average CARs for groups of supplier firms outside the EU for the five-day event window around December 13, 2022. CARs are calculated relative to CAPM expected returns. The different groups are composed as explained in Section 4.2, with the exception that the split between treatment and control groups is done at the 70% quantile of the $EU_customer_ratio$. Robust standard errors or p-values are reported in parentheses. In the first two columns, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In the last column, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

In fact, more than 50% of our sample have $EU_customer_ratio_j = 0$. For robustness, Table 12 presents results when we split the sample along the 70% quantile of $EU_customer_ratio_j$.²² Compared to Table 4, we find that the treatment effects are much larger in size. Interestingly, the difference between treatment group (fourth column) and the "industry treatment, location control" group (second column) is now strongly significant. This difference proxies for the incremental effect of the location treatment: we compare supplier firms in treated industries that have many versus only few customers within the EU. Overall, the results thus support the key takeaways from Section 4.2 that the financial performance of supplier firms is affected by the CBAM regulation as well and that the magnitude of the effect is comparable, if not larger than for EU customer firms.

 $^{^{22}\}mathrm{The}$ full set of results is documented in Table B.2 in Appendix B

7 Conclusion

In order to address the carbon leakage problem, the EU decided to complement the EU Emissions Trading System with a companion policy instrument – the EU Carbon Border Adjustment Mechanism (CBAM) – in 2023. The CBAM is the world's first carbon border tax and, ideally, levels the playing field for production inside and outside the EU in terms of carbon pricing.

This paper analyzes the stock price response of firms involved in international trade to the introduction of the CBAM in a causal event study around important legislative events. Quantitatively, our paper documents that the stock price responses of both suppliers and customers caused by the CBAM regulation are substantial, at the minimum -1 percent on average per event, depending on the exact specification of treatment and control group. Besides, we also document substantial anticipatory market responses reflecting updated beliefs about broader climate policy developments going forward, like the phasing-out of free allowances under the EU ETS or a broadening of the CBAM to further goods categories. Importantly, given the peculiarities of the empirical setup, the estimates presented in this paper should rather be regarded as a lower bound for the (unknown) total effect.

Our paper has several implications for policymakers. For instance, on a broader level, we provide evidence that EU climate policy which targets supplier firms outside the EU has spillover effects for customer firms located inside the EU. These spillover effects are also economically significant on aggregate, given that the EU accounts for 14% of the world's trade in goods. Moreover, our findings for the CBAM complements recent literature which documents that the EU ETS has had no measurable negative impact on the economic performance of regulated firms inside the EU during its first two phases.

Substitution elasticities within industries and product market competition might play an important role for these spillover effects. How the costs from the CBAM are shared ultimately depends on the relative market power of customers and suppliers. This market power, in turn, is determined by many factors, including the scarcity of the respective goods, the opportunity costs for replacing an existing customer-supplier relationship, as well as further regulations and policies, like changes in the EU ETS that are implemented in parallel with the CBAM. Given the limitations of our current dataset, we leave these issues open for future research.

Our paper also informs the broader debate about "stranded assets" resulting from the tightening of climate policies. Our empirical design does not allow us to disentangle whether the negative abnormal stock returns arise from a change in firms' expected cash flows or a change in their discount rates. One can make a case for both hypotheses. On the one hand, the financial burden from the CBAM will reduce the earnings of treated firms and thus affects expected cash flows. On the other hand, it can also increase the default probability of certain suppliers or customers whose business prospects rely heavily on the possibility of carbon leakage. If equity investors anticipate this default risk correctly, the cost of capital (a.k.a. discount rates) will increase, triggering negative announcement returns, just as we document them in our data.

Looking ahead, it seems plausible that other countries will follow the EU example – as it was also the case with the EU ETS back in 2005 – and also introduce carbon border taxes. Alternatively, but partly also as a response to the CBAM, a number of countries have joined the new climate club, which was founded by the G7 in 2022. In one or the other way, the EU CBAM has helped pave the way towards a globally harmonized carbon pricing system. In this regard, our results inform the respective political debates with quantitative evidence about the impact of climate policies on financial market expectations.

References

- AL KHOURDAJIE, A., AND M. FINUS (2020): "Measures to enhance the effectiveness of international climate agreements: The case of border carbon adjustments," *European Economic Review*, 124, 103405.
- ALLCOTT, H., C. KNITTEL, AND D. TAUBINSKY (2015): "Tagging and targeting of energy efficiency subsidies," *American Economic Review*, 105(5), 187–191.
- ANTWEILER, W., B. R. COPELAND, AND M. S. TAYLOR (2001): "Is free trade good for the environment?," *American economic review*, 91(4), 877–908.

- BEAUFILS, T., J. WANNER, AND L. WENZ (2024): "A carrot or a stick? The potential of carbon border adjustments to foster climate cooperation," *Working Paper*.
- BLANCHARD, O., C. GOLLIER, AND J. TIROLE (2023): "The portfolio of economic policies needed to fight climate change," *Annual Review of Economics*, 15(1), 689–722.
- BÖHRINGER, C., J. C. CARBONE, AND T. F. RUTHERFORD (2016): "The strategic value of carbon tariffs," *American Economic Journal: Economic Policy*, 8(1), 28–51.
- BÖHRINGER, C., C. FISCHER, K. E. ROSENDAHL, AND T. F. RUTHERFORD (2022): "Potential impacts and challenges of border carbon adjustments," *Nature Climate Change*, 12(1), 22–29.
- BOLTON, P., A. LAM, AND M. MUULS (2023): "Do carbon prices affect stock prices?," Working Paper.
- BUSHNELL, J. B., H. CHONG, AND E. T. MANSUR (2013): "Profiting from Regulation: Evidence from the European Carbon Market," American Economic Journal: Economic Policy, 5(4), 78â€"106.
- CALEL, R., AND A. DECHEZLEPRÊTRE (2016): "Environmental policy and directed technological change: evidence from the European carbon market," *Review of economics and statistics*, 98(1), 173–191.
- COHEN, L., K. DIETHER, AND C. MALLOY (2013): "Legislating stock prices," Journal of Financial Economics, 110(3), 574–595.
- COLMER, J., R. MARTIN, M. MUULS, AND U. J. WAGNER (2023): "Does Pricing Carbon Mitigate Climate Change? Firm-Level Evidence From the European Union Emissions Trading Scheme," forthcoming: Review of Economic Studies.
- CUI, J., C. WANG, J. ZHANG, AND Y. ZHENG (2021): "The effectiveness of China's regional carbon market pilots in reducing firm emissions," *Proceedings of the National Academy of Sciences*, 118(52), e2109912118.
- DE GROOTE, O., AND F. VERBOVEN (2019): "Subsidies and time discounting in new technology

adoption: Evidence from solar photovoltaic systems," *American Economic Review*, 109(6), 2137–2172.

- DECHEZLEPRETRE, A., C. GENNAIOLI, R. MARTIN, M. MUULS, AND T. STOERK (2022): "Searching for carbon leaks in multinational companies," *Journal of Environmental Economics* and Management, 112, 102601.
- DECHEZLEPRETRE, A., D. NACHTIGALL, AND F. VENMANS (2023): "The joint impact of the European Union emissions trading system on carbon emissions and economic performance," *Journal of Environmental Economics and Management*, 118(C).
- EDERINGTON, J., A. LEVINSON, AND J. MINIER (2005): "Footloose and pollution-free," *Review* of *Economics and Statistics*, 87(1), 92–99.
- ELLIOTT, J., I. FOSTER, S. KORTUM, T. MUNSON, F. P. CERVANTES, AND D. WEISBACH (2010): "Trade and carbon taxes," *American Economic Review*, 100(2), 465–469.
- ERNST, A., N. HINTERLANG, A. MAHLE, AND N. STÄHLER (2023): "Carbon pricing, border adjustment and climate clubs: Options for international cooperation," *Journal of International Economics*, 144, 103772.
- FARROKHI, F., AND A. LASHKARIPOUR (2024): "Can Trade Policy Mitigate Climate Change?," Working Paper.
- FISCHER, C., AND A. K. FOX (2012): "Comparing policies to combat emissions leakage: Border carbon adjustments versus rebates," *Journal of Environmental Economics and management*, 64(2), 199–216.
- FONTAGNE, L., AND K. SCHUBERT (2023): "The Economics of Border Carbon Adjustment: Rationale and Impacts of Compensating for Carbon at the Border," Annual Review of Economics, 15, 389–424.
- FOWLIE, M., C. PETERSEN, AND M. REGUANT (2021): "Border Carbon Adjustments When Carbon Intensity Varies across Producers: Evidence from California," AEA Papers and Proceedings, 111, 401–05.

- FOWLIE, M., M. REGUANT, AND S. P. RYAN (2016): "Market-based emissions regulation and industry dynamics," *Journal of Political Economy*, 124(1), 249–302.
- FOWLIE, M. L., AND M. REGUANT (2022): "Mitigating Emissions Leakage in Incomplete Carbon Markets," Journal of the Association of Environmental and Resource Economists, 9(2), 307– 343.
- FRANKEL, J. A., AND A. K. ROSE (2005): "Is trade good or bad for the environment? Sorting out the causality," *Review of economics and statistics*, 87(1), 85–91.
- GÓMEZ-CRAM, R., AND M. OLBERT (2023): "Measuring the expected effects of the global tax reform," *The Review of Financial Studies*, 36(12), 4965–5011.
- HUIMING ZHU, YIDING TANG, C. P., AND K. YU (2018): "The heterogeneous response of the stock market to emission allowance price: evidence from quantile regression," *Carbon Management*, 9(3), 277–289.
- JARAITE-KAUKAUSKE, J., AND C. D. MARIA (2016): "Did the EU ETS Make a Difference? An Empirical Assessment Using Lithuanian Firm-Level Data," *The Energy Journal*, Volume 37(Number 1).
- KLEMETSEN, M., K. E. ROSENDAHL, AND A. L. JAKOBSEN (2020): "The impacts of the EU ETS on Norwegian Plants' environmental and economic performance," *Climate Change Economics (CCE)*, 11(01), 1–32.
- LARCH, M., AND J. WANNER (2017): "Carbon tariffs: An analysis of the trade, welfare, and emission effects," *Journal of International Economics*, 109, 195–213.
- LOESCHEL, A., B. J. LUTZ, AND S. MANAGI (2019): "The impacts of the EU ETS on efficiency and economic performance – An empirical analyses for German manufacturing firms," *Resource and Energy Economics*, 56(C), 71–95.
- MARIN, G., M. MARINO, AND C. PELLEGRIN (2018): "The Impact of the European Emission Trading Scheme on Multiple Measures of Economic Performance," *Environmental & Resource Economics*, 71(2), 551–582.

- MARRON, D. B., AND E. J. TODER (2014): "Tax policy issues in designing a carbon tax," American Economic Review, 104(5), 563–568.
- MARTIN, R., L. B. DE PREUX, AND U. J. WAGNER (2014): "The impact of a carbon tax on manufacturing: Evidence from microdata," *Journal of Public Economics*, 117, 1–14.
- MARTIN, R., M. MUÛLS, AND U. J. WAGNER (2016): "The Impact of the European Union Emissions Trading Scheme on Regulated Firms: What Is the Evidence after Ten Years?," *Review of Environmental Economics and Policy*, 10(1), 129–148.
- MENG, K. C. (2017): "Using a free permit rule to forecast the marginal abatement cost of proposed climate policy," *American Economic Review*, 107(3), 748–784.
- MILLISCHER, L., T. EVDOKIMOVA, AND O. FERNANDEZ (2023): "The carrot and the stock: In search of stock-market incentives for decarbonization," *Energy Economics*, 120, 106615.
- MO, J.-L., L. ZHU, AND Y. FAN (2012): "The impact of the EU ETS on the corporate value of European electricity corporations," *Energy*, 45(1), 3–11.
- NAEGELE, H., AND A. ZAKLAN (2019): "Does the EU ETS cause carbon leakage in European manufacturing?," Journal of Environmental Economics and Management, 93, 125–147.
- NAKAMURA, E., AND J. STEINSSON (2018): "High-frequency identification of monetary nonneutrality: the information effect," *The Quarterly Journal of Economics*, 133(3), 1283–1330.
- NORDHAUS, W. (2015): "Climate clubs: Overcoming free-riding in international climate policy," American Economic Review, 105(4), 1339–1370.
- OBERNDORFER, U. (2009): "EU Emission Allowances and the stock market: Evidence from the electricity industry," *Ecological Economics*, 68(4), 1116–1126.
- OESTREICH, A. M., AND I. TSIAKAS (2015): "Carbon emissions and stock returns: Evidence from the EU Emissions Trading Scheme," *Journal of Banking and Finance*, 58, 294–308.
- PIERCE, J., AND P. SCHOTT (2012): "A concordance between ten-digit U.S. harmonized system codes and SIC/NAICS product classes and industries," *Journal of Economic and Social Measurement*, 37(1-2), 61–96.

SALIB, Y. (2024): "BCA and Reshuffling: A theoretical framework," Working Paper.

- SCHOLTENS, B., AND F. VAN DER GOOT (2014): "Carbon prices and firms' financial performance: an industry perspective," *Carbon Management*, 5(5-6), 491–505.
- SHAPIRO, J. S., AND R. WALKER (2018): "Why is pollution from US manufacturing declining? The roles of environmental regulation, productivity, and trade," *American Economic Review*, 108(12), 3814–3854.
- TEIXIDO, J., S. F. VERDE, AND F. NICOLLI (2019): "The impact of the EU Emissions Trading System on low-carbon technological change: The empirical evidence," *Ecological Economics*, 164, 106347.
- TRINKS, A., AND E. HILLE (2024): "Carbon costs and industrial firm performance: Evidence from international microdata," *Working Paper*.
- VAN DEN BREMER, T. S., AND F. VAN DER PLOEG (2021): "The risk-adjusted carbon price," American Economic Review, 111(9), 2782–2810.
- VEITH, S., J. R. WERNER, AND J. ZIMMERMANN (2009): "Capital market response to emission rights returns: Evidence from the European power sector," *Energy Economics*, 31(4), 605–613.
- WEISBACH, D. A., S. KORTUM, M. WANG, AND Y. YAO (2023): "Trade, Leakage, and the Design of a Carbon Tax," *Environmental and Energy Policy and the Economy*, 4, 43–90.

A Sectoral composition

			(1) Control group	(2) Generalized control group	(3) Treatment group
			$\begin{array}{c} loc_treat_ratio_i = 0 \&\\ ind_treat_ratio_i = 0 \end{array}$	$\begin{array}{l} loc_treat_ratio_i < median \ \& \\ ind_treat_ratio_i < median \end{array}$	$loc_treat_ratio_i > median \delta$ $ind_treat_ratio_i > median$
Mining		Total	4	11	15
	10	Metal	0	1	10
	12	Bituminous Coal and Lignite Mining	0	2	0
	13	Oil and Gas Extraction	4	7	4
	14	Mining and Quarrying of Nonmetallic Minerals, except Fuels	0	1	1
Manufacturing		Total	113	343	194
	20	Food and Kindred Products	6	20	7
	21	Tobacco Products	0	0	0
	22	Textile Mill Products	0	6	3
	23	Apparel and other Finished Products Made from Fabrics and Similar Materials	3	16	4
	24	Lumber and Wood Products, except Furniture	0	3	6
	25	Furniture and Fixtures	0	0	1
	26	Paper and Allied Products	2	9	4
	27	Printing, Publishing and Allied Industries	0	0	0
	28	Chemicals and Allied Products	26	52	31
	29	Petroleum Refining and Related Industries	0	1	1
	30	Rubber and Miscellaneous Plastics Products	1	3	6
	31	Leather and Leather Products	0	0	0
	32	Stone, Clay, Glass, and Concrete Products	4	9	8
	33	Primary Metal Industries	1	1	30
	34	Fabricated Metal Products, except Machinery and Transportation Equipment	2	10	22
	35	Industrial and Commercial Machinery and Computer Equipment	43	114	29
	36	Electronic and other Electrical Equipment and Components, except Computer Equipment	12	61	32
	37	Transportation Equipment	6	21	7
	38	Measuring, Analyzing, and Controlling Instruments; Photographic, Medical and Optical Goods; Watches and Clocks	6	12	3
	39	Miscellaneous Manufacturing Industries	1	5	0
Total		-	117	354	209

Table A.1: Sectoral Composition

Table A.1 reports the number of EU customer firms in our treatment and control groups by sector (2-digit SIC codes).

B Complete results

	(1)	(2)	(3)		(5)	(9)	(2)	(8)	(6)
	Control	Generalized	eatment	Location Treatment	Treatment	Industry	Industry	Location	Location
	$loc_treat_ratio_i = 0 \& ind_treat_ratio_i = 0$	$\begin{array}{llllllllllllllllllllllllllllllllllll$	$loc_{treat_ratio_i} < median & ind_{treat_ratio_i} > median$	$loc_{treat_ratio_i} > median & ind_treat_ratio_i < median$	to the transformation of transform	$\begin{array}{l} \textbf{Control}\\ ud_treat_ratio_i < median \end{array}$	Control Treatment Control Treatment ind.treat.ratio, < median	$\begin{array}{l} \textbf{Control}\\ loc_treat_ratio_i < median \end{array}$	Treatment loc_treat_ratio _i > medi
Mean	0.0035	0.000	-0.0069***	-0.0072	-0.0097***	-0.0036	-0.0083***	-0.0027	-0.0081***
\mathbf{SE}	(0.0036)	(0.0030)	(0.0025)	(0.0045)	(0.0030)	(0.0027)	(0.0020)	(0.0021)	(0.0031)
# Obs	117	354	217	362	209	716	426	571	571
				Panel B: Diffe	Panel B: Differences between groups	S			
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	(2)-(2)	(9)-(8)	
Mean	-0.0027	-0.0104^{***}	-0.0025	-0.0106^{*}	-0.0131^{***}	-0.0096**	-0.0046	-0.0054^{*}	
p-value	(0.2444)	(0.0088)	(0.3469)	(0.0982)	(0.0036)	(0.0164)	(0.1133)	(0.0724)	

exercise
baseline exercis
nces for the l
for
Ŀē
CAR diffe
Rs and
CARs
Table B.1:

reports differences between them. CARs are calculated relative to CAPM expected returns. The composition of the different treatment groups is the same as in Table 3, 7 and 6. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero, respectively.

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		(1)	(6)	(3)	(V)			(2)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		(1)	(7)	(e)	(4)	(n)	(n)		(o)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Control	Industry Treatment	Location Treatment	Treatment	Industry	Industry	Location	Location
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Location Control	Industry Control		Control	Treatment	Control	Treatment
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		$EU_customer_ratio_j = 0 \ \& ind_cbam_j = 0$	$EU_customer_ratio_{j} = 0 \ \& ind_cbam_{j} = 1$	$EU_customer_ratio_j = 1 \ \& ind_cbam_j = 0$	$EU_customer_ratio_{j} = 1 \& ind_cbam_{j} = 1$	$ind_cbam_j = 0$	$ind_cbam_j = 0$	$EU_customer_ratio_j = 0$	$EU_customer_ratio_j = 1$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			-0.0553***	-0.0567***	-0.0802***	-0.0586***	-0.0685***	-0.0599***	-0.0584***
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	SE	(0.0204)	(0.0160)	(0.0117)	(0.0150)	(0.0125)	(0.0110)	(0.0194)	(0.0109)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	# C		47	662	53	1498	100	883	715
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Control	Industry Treatment	Location Treatment	Treatment	Industry	Industry	Location	Location
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Location Control	Industry Control		Control	Treatment	Control	Treatment
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		$EU_customer_ratio_j < 70\%$ qtli & $ind_cbam_j = 0$	le $EU_customer_ratio_j < 70\%$ qtle $\& ind_cbam_j = 1$	$EU_customer_ratio_j > 70\%$ qtle & ind_cbam_j = 0	$EU_customer_ratio_j > 70\%$ qtle & ind_cbam_j = 1	$ind_cbam_j = 0$	$ind_cbam_j = 0$	$EU_customer_ratio_j$ $< 70\%$ qtle	$EU_customer_ratio_j > 70\%$ qtl
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	70 % quantile Mea		-0.0518^{***}	-0.0559^{***}	-0.0968***	-0.0586***	-0.0685***	-0.0593^{***}	-0.0591^{***}
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	split SE		(0.0133)	(0.0171)	(0.0183)	(0.0125)	(0.0110)	(0.0153)	(0.0159)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	# C		63	439	37	1498	100	1122	476
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$				Panel B: Different	ces between groups				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		4 - 4 - 4	1.1		con poor 9- order		2 - 2 - 2 - 2	1 2 4 2	
		(2)-(1)	(4)-(3)	(3)-(1)	(4)-(2)	(4)-(1)	(6)-(5)	(8)-(7)	
$ \begin{array}{c ccccc} & p-value & (0.4773) & (0.2859) & (0.4451) & (0.1291) & (0.4027) & (0.4196) \\ \\ & quantile & Mean & 0.0079 & -0.0409 & 0.0038 & -0.0450^{**} & -0.0371 & -0.0098 \\ & p-value & (0.4527) & (0.2455) & (0.4447) & (0.0234) & (0.3348) & (0.4196) \\ \end{array} $			-0.0235	0.0035	-0.0249	-0.0200	-0.0098	0.0015	
quantile Mean 0.0079 -0.0409 0.0038 -0.0450^{**} -0.0371 -0.0098 $-$ value (0.4527) (0.2455) (0.4447) (0.0234) (0.3348) (0.4196)	b-va		(0.2859)	(0.4451)	(0.1291)	(0.4027)	(0.4196)	(0.4751)	
p-value (0.4527) (0.2455) (0.4447) (0.2348) (0.4196)	70% quantile Mea		-0.0409	0.0038	-0.0450**	-0.0371	-0.0098	0.0002	
	split p-va	due (0.4527)	(0.2455)	(0.4447)	(0.0234)	(0.3348)	(0.4196)	(0.4968)	

Table B.2: CARs and CAR differences for non EU suppliers

in Table 4 and 12. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

	(1)	(2)	(3) (4) (5)	(4)	(2)	(9)	(2)	(8)	(6)
	Control	$\mathbf{Generalized}$	Industry Treatment	Industry Treatment Location Treatment	Tre	Industry	Industry	Location	Location
Event Dates		Control	Location Control	Industry Control		Control	Treatment	Control	Treatment
	$loc_treat_ratio_i = 0 \& ind_treat_ratio_i = 0$	$\label{eq:constraint} \begin{array}{llllllllllllllllllllllllllllllllllll$	$loc_treat_ratio_i < median \& ind_treat_ratio_i > median$	$loc_treat_ratio_i > median \& ind_treat_ratio_i < median$	$loc_treat_ratio_i > median \& ind_treat_ratio_i > median$		$ind_treat_ratio_i < \text{median} ind_treat_ratio_i > \text{median} loc_treat_ratio_i < \text{median} loc_treat_ratio_i > median$	$loc_treat_ratio_i < median$	$loc_treat_ratio_i > media$
July 14, 2021 Mean	0.0024	-0.0042	-0.0035	-0.0036	-0.0116	-0.0039	-0.0078	-0.0040	-0.0063*
SE	(0.0050)	(0.0050)	(0.0030)	(0.0028)	(0.0091)	(0.0029)	(0.0050)	(0.0036)	(0.0036)
# Obs	151	401	169	379	191	780	360	570	570
Feb 9, 2023 Mean	0.0011	0.0006	0.008	-0.0019	-0.0035	-0.0006	-0.0014	0.007	-0.0025
SE	(0.0040)	(0.0032)	(0.0035)	(0.0041)	(0.0043)	(0.0026)	(0.0028)	(0.0024)	(0.0030)
# Obs	112	343	212	359	216	702	428	555	575
April 18, 2023 Mean	0.007	0.0018	0.0065	-0.0144	-0.0175	-0.0061	-0.0065	0.0034	-0.0156
SE	(0.0049)	(0.0044)	(0.0042)	(0.0133)	(0.0186)	(0.008)	(0.0103)	(0.0032)	(0.0109)
# Obs	118	395	208	370	247	765	455	603	617
				Panel B: Differences between groups	s between groups				
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	(2)-(2)	(8)-(8)	
July 14, 2021 Mean	-0.0082	-0.0061	-0.0080	-0.0059	-0.0140	-0.0074	-0.0039	-0.0023	
p-value	(0.2099)	(0.1315)	(0.1457)	(0.1510)	(0.1047)	(0.2207)	(0.2410)	0.3243	
Feb 9, 2023 Mean	-0.0043	-0.0003	-0.0016	-0.0029	-0.0046	-0.0042	-0.0007	-0.0032	
p-value	(0.2177)	(0.4823)	(0.3961)	(0.3503)	(0.2429)	(0.2148)	(0.4274)	(0.2036)	
April 18, 2023 Mean	-0.0240	0.0058	-0.0031	-0.0151	-0.0182	-0.0193	-0.0005	-0.0190^{**}	
p-value	(0.1223)	(0.1941)	(0.4439)	(0.2620)	(0.2509)	(0.1098)	(0.4834)	(0.0484)	

Table B.3: CARs and CAR differences on the other event dates

as in Table 5. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero.

Generalized control group $treat_ratio_i < median \& a_{treat_ratio_i} < median$	Universal Treatment group loc_treat_ratio_i > median Or ind_treat_ratio_i > median	$\begin{array}{l} \textbf{Beliefs Updating} \\ \textbf{Treatment} \\ \textbf{Treatment} \\ \textbf{I} \\ \textbf{for} \\ $	—	Difference Difference Difference Difference $(3) - (1)$ $(3) - (2)$ $(4) - (1)$ $(4) - (2)$	$\mathbf{Difference}$ (4) - (1)	Difference $(4) - (2)$
-	c_treat_ratio; > median Of ind_treat_ratio; > median	loc_treat_ratio _i = 0 & loc_treat_ratio _i < median & loc_treat_ratio _i > median OT (loc_treat_ratio _i < median & ind_treat_ratio _i > median) or ind_treat_ratio _i = 0 ind_treat_ratio _i < median ind_treat_ratio _i > median (loc_treat_ratio _i > median & ind_treat_ratio _i < median)				
	-0.0078^{+++} (0.0023)	(0.0030)			-0.007	-0700.0
			0.0354	0	0.0271	0.0271 0.0615
	788	579				

Table B.4: Broad Treatment Group

Table B.4 reports the average CARs and their difference between different groups for the five-day event window around December 13, 2022. CARs are calculated relative to CAPM expected returns. Robust standard errors or p-values are reported in parentheses. For the columns with mean CARs, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. For the columns with differences, they refer to one-sided t-tests of the null hypothesis of the mean being equal to zero. For the

	(1)	(0)	(0)				(1)	(8)	(0)
	(T)	(2)	(3)	(4)	(c)	(0)	9	(&)	(8)
	Control	Generalized Control	Industry Treatment Location Control	Location Treatment Industry Control	Treatment	Industry Control	Industry Treatment	Lo cation Control	Location Treatment
	$\begin{array}{l} loc_treat_ratio_i = 0 \ \& \\ ind_treat_ratio_i = 0 \end{array}$	$loc_treat_ratio_i < median \& ind_treat_ratio_i < median$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	$loc_treat_ratio_i > median \& ind_treat_ratio_i < median$	loc treat ratio, > median & loc treat ratio, > median & ind treat ratio, < median ind treat ratio, > median loc treat r	$rd_{treat ratio_i} < median$	$ind_treat_ratio_i > median$	$loc_treat_ratio_i < median$	$loc_treat_ratio_i > medis$
Mean	-0.0215*	-0.0145^{***}	-0.0091^{*}	-0.0242^{***}	-0.0271^{***}	-0.0194^{***}	-0.0179^{***}	-0.0124^{***}	-0.0252^{***}
	(0.0118)	(0.0052)	(0.0048)	(0.0061)	(0.0054)	(0.0040)	(0.0036)	(0.0037)	(0.0043)
# Obs	117	354	217	362	209	716	426	571	571
				Panel B: Diffe	Panel B: Differences between groups	ß			
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	(2)-(2)	(9)-(8)	
Mean	-0.0180^{***}	0.0125	-0.0029	-0.0027	-0.0056	-0.0125^{*}	0.0015	-0.0128^{**}	
p-value	(0.0065)	(0.1263)	(0.3725)	(0.4168)	(0.3119)	(0.0577)	(0.5989)	(0.0127)	

Table B.5: CARs and CAR differences for ten-day event window

as in Table 8. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of reports differences between them. CARs are calculated relative to CAPM expected returns. The composition of the different treatment groups is the same the mean difference being positive or negative, repectively.

				I mind the training of the tot of the back	June Prove for married				
	(1)	(2)	(3)	(4)	(5)	(9)	(2)	(8)	(6)
	Control	Generalized	Industry Treatment	Industry Treatment Location Treatment	Treatment	Industry	Industry	Location	Location
		Control	Location Control	Industry Control		Control	Treatment	Control	Treatment
	$loc_treat_ratio_i = 0 \& ind_treat_ratio_i = 0$	<pre>: loc_treat_ratio_i <x% &="" ind_treat_ratio<sub="" qtle="">i < x% qtle</x%></pre>	$\begin{array}{llllllllllllllllllllllllllllllllllll$	<pre>loc_treat_ratio_i > x% qtle & ind_treat_ratio_i < x% qtle</pre>	<pre>loc_treat_ratio_i > x% qtle & ind_treat_ratio_i > x% qtle</pre>	$ind_treat_ratio_i < x\%$ qtle	$ind.reat.ratio_i < x\%$ gtle $ind.treat.ratio_i > x\%$ gtle $loc.treat.ratio_i < x\%$ gtle $loc.treat.ratio_i > x\%$ gtle $ind.treat.ratio_i > x\%$ gtle $ind.t$	$loc.treat.ratio_i < x\%$ qtle	$loc_treat_ratio_i > x\% qt$
70% quantile Mean	0.0035	-0.0039	-0.0077***	-0.0062	-0.0055	-0.0046*	-0.0072^{***}	-0.0051^{***}	-0.0060
split SE	(0.0036)	(0.0027)	(0.0022)	(0.0050)	(0.0061)	(0.0025)	(0.0022)	(0.0020)	(0.0041)
# Obs		546	254°	262	, 80	808	334	800	342
30% quantile Mean	0.0035	0.0027	-0.0080**	-0.0066***	-0.0084^{***}	-0.0036	-0.0083***	-0.0010	-0.0073***
split SE	(0.0036)	(0.0039)	(0.0037)	(0.0036)	(0.0023)	(0.0027)	(0.0020)	(0.0028)	(0.0024)
# Obs	117	228	120	488	306	716	426	348	794
				Panel B: Differences between groups	s between groups				
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	(2)-(2)	(9)-(8)	
70% quantile Mean	0.0023	-0.0112^{***}	0.0007	-0.007	-0.0090*	-0.0016	-0.0026	-0.009	
split p-value	(0.3325)	(0.0032)	(0.4713)	(0.1097)	(0.0899)	(0.4148)	(0.2630)	(0.4101)	
30% quantile Mean	-0.004	-0.0115^{**}	-0.0018	-0.0101*	-0.0119^{***}	-0.0111^{***}	-0.0046	-0.0063*	
split p-value	(0.4619)	(0.0141)	(0.3539)	(0.0892)	(0.0035)	(0.0050)	(0.1133)	(0.0599)	

Table B.6: CARs and CAR differences using alternative specification of treatment and control

as in Table 9. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of the mean difference being positive or zero. reports differences between them. CARs are calculated relative to CAPM expected returns. The composition of the different treatment groups is the same

	(1)	(2)	(3)	(4)	(5)	(9)	(2)	(8)	(6)
	Control	Generalized	Industry Treatment Location Treatment	Location Treatment	Treatment	Industry	Industry	Location	Location
		Control	Location Control	Industry Control		Control	Treatment	Control	Treatment
loc.t. ind	$treat_ratio_i = 0 \&$ $l_treat_ratio_i = 0$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	loc_tre ind_tr	$loc_treat_ratio_i > median \& ind_treat_ratio_i < median$	$loc.treat.ratio_i > median \ k \ ind.treat.ratio_i < median \ ind.treat.ratio_i < median \ loc.treat.ratio_i < median \ loc.treat.ratio_i < median \ loc.treat.ratio_i > median \ loc.treat.ratio_i < median \ loc.treat.$	$ind_treat_ratio_i < \mathrm{median}$	$ind_treat_ratio_i > median$	$loc_treat_ratio_i < \mathrm{median}$	$loc_treat_ratio_i > media$
1 month Mean	0.0034	-0.002	-0.0069***	-0.0085*	-0.0099***	-0.0044	-0.0084^{***}	-0.0027	-0.0091^{***}
SE	(0.0036)	(0.0029)	(0.0025)	(0.0047)	(0.0030)	(0.0028)	(0.0020)	0.0021	0.0031
# Obs	118	358	216	361	213	719	429	574	574
2 month Mean	0.0039	-0.009	-0.0070***	-0.0075	-0.0097***	-0.0043	-0.0083***	-0.0032	-0.0083***
\mathbf{SE}	(0.0035)	(0.0029)	(0.0026)	(0.0046)	(0.0021)	0.0028	0.0019	0.0020	0.0031
# Obs	117	348	214	375	220	723	434	562	595
3 month Mean	0.0053	-0.0005	-0.0059	-0.0047	-0.0091^{***}	-0.0027	-0.0076***	-0.0026	-0.0063*
\mathbf{SE}	(0.0035)	(0.0029)	(0.0029)	(0.0053)	(0.0029)	(0.0031)	(0.0021)	(0.0021)	(0.0035)
# Obs	119	351	218	377	221	728	439	569	598
				Panel B: Differenc	Panel B: Differences between groups				
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	$(2)^{-}(2)$	(9)-(8)	
1 month Mean	-0.0030	-0.0103^{***}	-0.0014	-0.0119^{*}	-0.0133^{***}	-0.0097**	-0.0041	-0.0063^{**}	
p-value	(0.2233)	(0.0090)	(0.4144)	(0.0789)	(0.0031)	(0.0145)	(0.1487)	(0.0465)	
2 month Mean	-0.0027	-0.0108^{***}	-0.0021	-0.0114^{*}	-0.0135^{***}	-0.0088*	-0.0040	-0.0051^{*}	
p-value	(0.2458)	(0.0066)	(0.3699)	(0.0881)	(0.0025)	(0.0217)	(0.1503)	(0.0854)	
3 month Mean	-0.0032	-0.0112^{***}	-0.0044	-0.0100	-0.0144^{***}	-0.0087**	-0.0049	-0.0038	
p-value	(0.2192)	(0.0095)	(0.2715)	(0.1515)	(0.0012)	(0.0223)	(0.1271)	(0.1822)	

Table B.7: CARs and CAR differences allowing for customer-supplier relationships ending before event dates

55

the mean difference being positive or zero.

	(1)	(2)	(3)	(4)	(e)	(0)	(\cdot)	(8)	(9)
	Control	Generalized Control	Industry Treatment Location Control	Industry Treatment Location Treatment Location Control Industry Control	Treatment	Industry Control	Industry Treatment	Location	Location Treatment
	$loc_treat_ratio_i = 0 \& ind_treat_ratio_i = 0$	$\label{eq:loc_treat_ratio_i < median & \\ ind_treat_ratio_i < median \\ \end{array}$	$\begin{array}{llllllllllllllllllllllllllllllllllll$	<i>loc_treat_ratio</i> _i > median & <i>ind_treat_ratio</i> _i < median	$loc_treat_ratio_i > median \& ind_treat_ratio_i > median$		ind_freat_ratioi < median ind_freat_ratioi > median loc_treat_ratioi < median loc_freat_ratioi > median	$loc_treat_ratio_i < median$	$loc_treat_ratio_i > media$
FF3 Mean	-0.0002	-0.0033	-0.0092^{***}	-0.0114^{***}	-0.0109^{***}	-0.0074^{***}	-0.0101^{***}	-0.0056^{***}	-0.0112^{***}
SE	(0.0035)	(0.0029)	(0.0025)	(0.0045)	(0.0037)	(0.0027)	(0.0022)	(0.0020)	(0.0031)
# Obs	117	354	217	362	209	716	426	571	571
FF5 Mean	-0.0006	-0.0041	-0.0094^{***}	-0.0122^{***}	-0.0119^{***}	-0.0082^{***}	-0.0106^{***}	-0.0061^{***}	-0.0121^{***}
SE	(0.0036)	(0.0028)	(0.0025)	(0.0045)	(0.0033)	(0.0027)	(0.0021)	(0.0020)	(0.0031)
				Panel B: Differe	Panel B: Differences between groups	s			
	(5)-(3)	(3)-(1)	(5)-(4)	(4)-(1)	(5)-(1)	(5)-(2)	$(2)^{-(2)}$	(9)-(8)	
FF3 Mean	-0.0017	-0.0000**	0.0005	-0.0113^{*}	-0.0108**	-0.0076*	-0.0026	-0.0057*	
p-value	(0.3467)	(0.0179)	(0.4711)	(0.0824)	(0.0277)	(0.0531)	(0.2477)	(0.0639)	
FF5 Mean	-0.0025	-0.0088**	0.0003	-0.0116^{*}	-0.0113^{**}	-0.0078**	-0.0025	-0.0060*	
p-value	(0.2762)	(0.0212)	(0.4823)	(0.0773)	(0.0151)	(0.0403)	(0.2574)	(0.0518)	

Ň
tor
fac
Ŋ
and
 ന
French
Fama
\mathbf{to}
relative
CAR differences
\mathbf{AR}
C
and
8: CARs
e B.8:
Table

as in Table 11. Robust standard errors or p-values are reported in parentheses. In Panel A, stars indicating statistical significance (*** p<0.01, ** p<0.05, * p<0.1) refer to two-sided t-tests of the null hypothesis of the mean being equal to zero. In Panel B, they refer to one-sided t-tests of the null hypothesis of Panel A in Table B.8 reports the average CARs for each group of EU customer firms for the five-day event window around the other event dates. Panel B reports differences between them. CARs are calculated relative to CAPM expected returns. The composition of the different treatment groups is the same the mean difference being positive or zero.